WO2003077858A2 - Humanized antibodies that recognize beta amyloid peptide - Google Patents
Humanized antibodies that recognize beta amyloid peptide Download PDFInfo
- Publication number
- WO2003077858A2 WO2003077858A2 PCT/US2003/007715 US0307715W WO03077858A2 WO 2003077858 A2 WO2003077858 A2 WO 2003077858A2 US 0307715 W US0307715 W US 0307715W WO 03077858 A2 WO03077858 A2 WO 03077858A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- immunoglobulin
- seq
- residue
- heavy chain
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title claims description 49
- 238000000034 method Methods 0.000 claims abstract description 131
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 73
- 201000010099 disease Diseases 0.000 claims abstract description 67
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 41
- 210000004556 brain Anatomy 0.000 claims abstract description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 178
- 102000018358 immunoglobulin Human genes 0.000 claims description 178
- 230000027455 binding Effects 0.000 claims description 145
- 150000001413 amino acids Chemical class 0.000 claims description 106
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 90
- 239000000427 antigen Substances 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- 238000006467 substitution reaction Methods 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 68
- 208000024827 Alzheimer disease Diseases 0.000 claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 230000001225 therapeutic effect Effects 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 33
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 32
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 32
- 230000003942 amyloidogenic effect Effects 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 239000012636 effector Substances 0.000 claims description 31
- 230000004044 response Effects 0.000 claims description 31
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 125000000539 amino acid group Chemical group 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 241001529936 Murinae Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 206010057249 Phagocytosis Diseases 0.000 claims description 19
- 230000008782 phagocytosis Effects 0.000 claims description 19
- 230000000295 complement effect Effects 0.000 claims description 16
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 14
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 14
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 14
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 14
- 230000009870 specific binding Effects 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 6
- 108010079585 Immunoglobulin Subunits Proteins 0.000 claims description 6
- 102000012745 Immunoglobulin Subunits Human genes 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010044688 Trisomy 21 Diseases 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 208000028698 Cognitive impairment Diseases 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 230000004797 therapeutic response Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 208000000340 Alzheimer disease type 1 Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 67
- 230000001976 improved effect Effects 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 86
- 229940024606 amino acid Drugs 0.000 description 80
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 229940072221 immunoglobulins Drugs 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 230000000694 effects Effects 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 29
- 238000003556 assay Methods 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 25
- 102000009109 Fc receptors Human genes 0.000 description 22
- 108010087819 Fc receptors Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 21
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 21
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000000306 component Substances 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 229940124597 therapeutic agent Drugs 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 13
- 230000000069 prophylactic effect Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 9
- 230000004075 alteration Effects 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000001539 phagocyte Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000005094 computer simulation Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- -1 his Chemical compound 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002981 neuropathic effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 102220335925 rs775094277 Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102220493683 HLA class II histocompatibility antigen, DRB1 beta chain_V67L_mutation Human genes 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 102200087445 rs566961335 Human genes 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102220582751 Glutathione S-transferase Mu 4_G27S_mutation Human genes 0.000 description 2
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 2
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 102220488187 Olfactory receptor 2A12_I29L_mutation Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010050254 Presenilins Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 102200082932 rs33929459 Human genes 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 101800001718 Amyloid-beta protein Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000612288 Pinus strobus Putative oxygen-evolving enhancer protein 1 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000738583 Senna artemisioides Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000133063 Trixis Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000003008 brain-resident macrophage Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 102000046783 human APP Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000031339 positive regulation of inflammatory response Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220188881 rs747642461 Human genes 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- Alzheimer's disease is a progressive disease resulting in senile dementia
- AD Alzheimer's disease
- TINS 16 403 (1993), Hardy et al , WO 92/13069, Selkoe, J Neuropathol Exp Neurol 53 438 (1994), Duffer al , Nature 373 476 (1995), Games et al , Nature 373 523 (1995)
- the disease falls into two categories late onset, which occurs in old age (65 + years) and early onset, which develops well before the se le period, i e , between 35 and 60 years hi both types of disease, the pathology is the same but the abnormalities tend to be more severe and widespread in cases beginning at an earlier age
- the disease is charactenzed by at least two types of lesions in the brain, neurofibrillary tangles and senile plaques Neurofib ⁇ llary tangles are intracellular deposits of microtubule associated tau protein consisting of two filaments twisted about each other
- Such mutations are thought to cause Alzheimer's disease by increased or altered processing of APP to A ⁇ , particularly processing of APP to increased amounts of the long form of A ⁇ (i.e., A ⁇ l-42 and A ⁇ l-43). Mutations in other genes, such as the presenilin genes, PS1 and PS2, are thought indirectly to affect processing of APP to generate increased amounts of long form A ⁇ (see Hardy, TINS 20: 154 (1997)). Mouse models have been used successfully to determine the significance of amyloid plaques in Alzheimer's (Games et al., supra, Johnson- Wood et al., Proc. Natl. Acad. Sci. USA 94:1550 (1997)).
- PDAPP transgenic mice which express a mutant form of human APP and develop Alzheimer's disease at a young age
- a ⁇ particularly in its long form, is a causative element in Alzheimer's disease.
- therapies and reagents for the treatment of Alzheimer's disease in particular, therapies and reagents capable of effecting a therapeutic benefit at physiologic (e.g., non-toxic) doses.
- the present invention features new immunological reagents, in particular, therapeutic antibody reagents for the prevention and treatment of amyloidogenic disease (e.g., Alzheimer's disease).
- the invention is based, at least in part, on the identification and characterization of a monoclonal antibody that specifically binds to A ⁇ peptide and is effective at reducing plaque burden and/or reducing the neu ⁇ tic dystrophy associated with amyloidogenic disorders Structural and functional analysis of this antibody leads to the design of various humamzed antibodies for prophylactic and/or therapeutic use
- the invention features humamzation of the va ⁇ able regions of this antibody and, accordingly, provides for humanized immunoglobulin or antibody chains, intact humanized immunoglobulins or antibodies, and functional immunoglobulin or antibody fragments, in particular, antigen binding fragments, of the featured antibody
- Polypeptides comp ⁇ sing the complementa ⁇ ty determining regions of the featured monoclonal antibody are also disclosed, as are polynucleotide reagents, vectors and host cells suitable for encoding said polypeptides
- amyloidogenic diseases or disorders e g , Alzheimer's disease
- pharmaceutical compositions and kits for use in such applications are disclosed, as are pharmaceutical compositions and kits for use in such applications
- antibodies e g , humanized antibodies having altered effector functions, and therapeutic uses thereof
- Figure 1A-B depicts an alignment of the ammo acid sequences of the light chain of mouse 12B4 (mature peptide, SEQ ID NO 2), humanized 12B4 (mature peptide, SEQ ID NO 6), Kabat ID 005036 (mature peptide, SEQ ID NO 32) and germhne A19 (X63397, mature peptide, SEQ ID NO 30) antibodies CDR regions are stippled and overhned The single backmutation of a human — > mouse residue is indicated by the asterisk The importance of the shaded residues is shown in the legend Numbered from the first methiomne, not Kabat numbenng
- Figure 2A-B depicts an alignment of the amino acid sequences of the heavy chain of mouse 12B4 (mature peptide, SEQ ID NO 4), humanized 12B4 (version 1) (mature peptide, SEQ ID NO 8), Kabat ID 000333 (mature peptide, SEQ ID NO 34), and germhne VH4-39 and
- Figure 3A-D depicts the nucleotide and amino acid sequence for humanized 12B4VLvl compared with chime ⁇ c 12B4VL (identical va ⁇ able region sequences as mu ⁇ ne 12B4VL, SEQ ID NOs 1 and 2, respectively), germhne A19 sequences (SEQ ID NOs 29 and 30, respectively), and Kabid ID 005036 (SEQ ID NOs 31 and 32, respectively)
- Figure 4A-D depicts the nucleotide and amino acid sequence for humanized 12B4VHvl compared with chime ⁇ c 12B4VH (identical va ⁇ able region sequences as mu ⁇ ne 12B4VH, SEQ ID NOs 3 and 4, respectively), Kabat ID 000333 (SEQ ID NOs 33 and 34, respectively), and germhne VH4-61 (SEQ ID NOs 35 and 36, respectively)
- Figure 5 graphically depicts the ELISA results from two independent expe ⁇ ments measu ⁇ ng the binding of chime ⁇ c 12B4, 3D6, and chime ⁇ c 3D6 to A ⁇ (panels A and B, respectively)
- Figure 6 graphically depicts competitive ELISA binding confirming functional activity of 12B4 and chime ⁇ c 12B4 as compared to 3D6, chimenc 3D6, and 10D5 Chime ⁇ c 12B4 (open t ⁇ angles) competes with equal potency with its non biotinylated mu ⁇ ne counterpart (open inverted t ⁇ angles) for binding of biotinylated munne 12B4 to A ⁇ 1 -42 peptide
- Figure 7 graphically depicts an ex vivo phagocytosis assay testing the ability of chime ⁇ c 12B4, 3D6, and human IgGl to mediate the uptake of A ⁇ by microghal cells on PDAPP brain sections
- Figure 8 graphically depicts the results from two independent ex vivo phagocytosis assays (panels A and B, respectively) testing the ability of chimeric 12B4, humanized 3D6, and human IgGl to mediate the uptake of A ⁇ by microghal cells on AD brain sections
- Figure 9 is a schematic representation of the PCR-mediated assembly of humanized 12B4, version 1 Figure 9 A depicts the assembly of the VL regions Figure 9B depicts the assembly of the VH regions Detailed Description of the Invention
- the present invention features new immunological reagents and methods for preventing or treating Alzheimer's disease or other amyloidogenic diseases.
- the invention is based, at least in part, on the characterization of a monoclonal immunoglobulin, 12B4, effective at binding beta amyloid protein (A ⁇ ) (e.g. , binding soluble and/or aggregated A ⁇ ), mediating phagocytosis (e.g., of aggregated A ⁇ ), reducing plaque burden and/or reducing neuritic dystrophy (e.g., in a patient).
- a ⁇ beta amyloid protein
- the invention is further based on the determination and structural characterization of the primary and secondary structure of the variable light and heavy chains of the 12B4 immunoglobulin and the identification of residues important for activity and immunogenicity.
- Immunoglobulins are featured which include a variable light and/or variable heavy chain of the 12B4 monoclonal immunoglobulin described herein.
- Preferred immunoglobulins e.g., therapeutic immunoglobulins, are featured which include a humanized variable light and/or humanized variable heavy chain.
- Preferred variable light and/or variable heavy chains include a complementarity determining region (CDR) from the 12B4 immunoglobulin (e.g., donor immunoglobulin) and variable framework regions substantially from a human acceptor immunoglobulin.
- CDR complementarity determining region
- substantially from a human acceptor immunoglobulin means that the majority or key framework residues are from the human acceptor sequence, allowing however, for substitution of residues at certain positions with residues selected to improve activity of the humanized immunoglobulin (e.g., alter activity such that it more closely mimics the activity of the donor immunoglobulin) or selected to decrease the immunogenicity of the humanized immunoglobulin.
- the invention features a humanized immunoglobulin light or heavy chain that includes 12B4 variable region complementarity determining regions (CDRs) (i.e., includes one, two or three CDRs from the light chain variable region sequence set forth as SEQ ID NO:2 or includes one, two or three CDRs from the heavy chain variable region sequence set forth as SEQ ID NO:4), and includes a variable framework region substantially from a human acceptor immunoglobulin light or heavy chain sequence, provided that at least one residue of the framework residue is backmutated to a corresponding murine residue, wherein said backmutation does not substantially affect the ability of the chain to direct A ⁇ binding.
- CDRs 12B4 variable region complementarity determining regions
- the invention features a humanized immunoglobulin light or heavy chain that includes 12B4 variable region complementarity determining regions (CDRs) (e.g., includes one, two or three CDRs from the light chain variable region sequence set forth as SEQ ID NO:2 and/or includes one, two or three CDRs from the heavy chain variable region sequence set forth as SEQ ID NO:4), and includes a variable framework region substantially from a human acceptor immunoglobulin light or heavy chain sequence, provided that at least one framework residue is substituted with the corresponding amino acid residue from the mouse 12B4 light or heavy chain variable region sequence, where the framework residue is selected from the group consisting of (a) a residue that non-covalently binds antigen directly; (b) a residue adjacent to a CDR; (c) a CDR-interacting residue (e.g., identified by modeling the light or heavy chain on the solved structure of a homologous known immunoglobulin chain); and (d) a residue participating in the VL-VH interface.
- the invention features a humanized immunoglobulin light or heavy chain that includes 12B4 variable region CDRs and variable framework regions from a human acceptor immunoglobulin light or heavy chain sequence, provided that at least one framework residue is substituted with the co ⁇ esponding amino acid residue from the mouse 12B4 light or heavy chain variable region sequence, where the framework residue is a residue capable of affecting light chain variable region conformation or function as identified by analysis of a three- dimensional model of the variable region, for example a residue capable of interacting with antigen, a residue proximal to the antigen binding site, a residue capable of interacting with a CDR, a residue adjacent to a CDR, a residue within 6 A of a CDR residue, a canonical residue, a vernier zone residue, an interchain packing residue, an unusual residue, or a glycoslyation site residue on the surface of the structural model.
- the framework residue is a residue capable of affecting light chain variable region conformation or function as identified by analysis of a three- dimensional model
- the invention features, in addition to the substitutions described above, a substitution of at least one rare human framework residue.
- a rare residue can be substituted with an amino acid residue which is common for human variable chain sequences at that position.
- a rare residue can be substituted with a corresponding amino acid residue from a homologous germline variable chain sequence.
- the invention features a humanized immunoglobulin that includes a light chain and a heavy chain, as described above, or an antigen-binding fragment of said immunoglobulin.
- the humanized immunoglobulin binds (e.g., specifically binds) to beta amyloid peptide (A ⁇ ) with a binding affinity of at least 10 7 M "1 , 10 8 M “1 , or 10 9 M "1 .
- the immunoglobulin or antigen binding fragment includes a heavy chain having isotype ⁇ l.
- the immunoglobulin or antigen binding fragment binds (e.g., specifically binds) to both soluble beta amyloid peptide (A ⁇ ) and aggregated A ⁇ .
- the immunoglobulin or antigen binding fragment mediates phagocytosis (e.g., induces phagocytosis) of beta amyloid peptide (A ⁇ ).
- the immunoglobulin or antigen binding fragment crosses the blood-brain barrier in a subject.
- the immunoglobulin or antigen binding fragment reduces both beta amyloid peptide (A ⁇ ) burden and neuritic dystrophy in a subject.
- the invention features chimeric immunoglobulins that include 12B4 variable regions (e.g., the variable region sequences set forth as SEQ ID NO:2 or SEQ ED NO:4).
- the immunoglobulin, or antigen-binding fragment thereof further includes constant regions from IgGl.
- the immunoglobulins described herein are particularly suited for use in therapeutic methods aimed at preventing or treating amyloidogenic diseases.
- the invention features a method of preventing or treating an amyloidogenic disease (e.g., Alzheimer's disease) that involves administering to the patient an effective dosage of a humanized immunoglobulin as described herein.
- an amyloidogenic disease e.g., Alzheimer's disease
- the invention features pharmaceutical compositions that include a humanized immunoglobulin as described herein and a pharmaceutical carrier.
- the present invention further features a method for identifying 12B4 residues amenable to substitution when producing a humanized 12B4 immunoglobulin, respectively.
- a method for identifying variable framework region residues amenable to substitution involves modeling the three-dimensional structure of a 12B4 va ⁇ able region on a solved homologous immunoglobulin structure and analyzing said model for residues capable of affecting 12B4 immunoglobulin variable region conformation or function, such that residues amenable to substitution are identified
- the invention further features use of the va ⁇ able region sequence set forth as SEQ ED NO 2 or SEQ ID NO 4, or any portion thereof, in producing a three-dimensional image of a 12B4 immunoglobulin, 12B4 immunoglobulin chain, or domain thereof
- the present invention further features immunoglobulins having altered effector function, such as the ability to bind effector molecules, for example, complement or a receptor on an effector cell
- the immunoglobulin of the invention has an altered constant region, e g , Fc region, wherein at least one amino acid residue in the Fc region has been replaced with a different residue or side chain
- the modified immunoglobulin is of the IgG class, comp ⁇ ses at least one amino acid residue replacement in the Fc region such that the immunoglobulin has an altered effector function, e g , as compared with an unmodified immunoglobulin
- the immunoglobulin of the invention has an altered effector function such that it is less immunogenic (e g , does not provoke undesired effector cell activity, lysis, or complement binding), has improved amyloid clearance properties, and/or has a desirable half-life P ⁇ or to desc ⁇ bing the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be
- immunoglobulin or “antibody” (used interchangeably herein) refers to a protein having a basic four-polypeptide chain structure consisting of two heavy and two light chains, said chains being stabilized, for example, by interchain disulfide bonds, which has the ability to specifically bind antigen
- single- chain immunoglobulin or “single-chain antibody” (used interchangeably herein) refers to a protein having a two-polypeptide chain structure consisting of a heavy and a light chain, said chains being stabilized, for example, by interchain peptide linkers, which has the ability to specifically bind antigen
- domain refers to a globular region of a heavy or light chain polypeptide comp ⁇ sing peptide loops (e g , compnsing 3 to 4 peptide loops) stabilized, for example, by ⁇ -pleated sheet and/or intrachain disulfide bond Domains are further referred to herein as "constant" or
- region can also refer to a part or portion of an antibody chain or antibody chain domain (e g , a part or portion of a heavy or light chain or a part or portion of a constant or va ⁇ able domain, as defined herein), as well as more discrete parts or portions of said chains or domains
- light and heavy chains or light and heavy chain variable domains include "complementarity determining regions" or "CDRs" interspersed among "framework regions” or "FRs", as defined herein
- Immunoglobulins or antibodies can exist in monome ⁇ c or polymenc form, for example, IgM antibodies which exist in pentame ⁇ c form and/or IgA antibodies which exist in monomeric, dime ⁇ c or multime ⁇ c form
- fragment refers to a part or portion of an antibody or antibody chain comp ⁇ sing fewer amino acid residues than an intact or complete antibody or antibody chain Fragments can be obtained via chemical or enzymatic treatment of an intact or complete antibody or antibody chain Fragments can also be obtained by recombinant means Exemplary fragments include Fab, Fab', F(ab')2, Fabc and/or Fv fragments
- antigen-bmding fragment refers to a polypeptide fragment of an immunoglobulin or antibody that binds antigen or competes with intact antibody (i e , with the intact antibody from which they were de ⁇ ved) for antigen binding (i e , specific binding)
- formation refers to the tertiary structure
- Specific binding of an antibody mean that the antibody exhibits appreciable affinity for antigen or a preferred epitope and, preferably, does not exhibit significant crossreactivity
- Appreciable or preferred binding include binding with an affinity of at least 10 6 , 10 7 , 10 s , 10 9 M ', or 10 10 M ' Affinities greater than 10 7 M ', preferably greater than 10 8 M ' are more preferred Values intermediate of those set forth herein are also intended to be within the scope of the present invention and a preferred binding affinity can be indicated as a range of affinities, for example, 10 ⁇ to 10 10 M ', preferably 10 7 to 10 10 M ⁇ more preferably 10 s to 10 10 M '
- An antibody that "does not exhibit significant crossreactivity" is one that will not appreciably bind to an undesirable entity (e g , an undesirable proteinaceous entity)
- an antibody that specifically binds to A ⁇ will appreciably bind A ⁇ but will not significantly react with non-A ⁇ proteins or peptid
- substantially from a human immunoglobulin or antibody or “substantially human” means that, when aligned to a human immunoglobulin or antibody amino sequence for compa ⁇ son purposes, the region shares at least 80-90%, preferably at least 90-95%, more preferably at least 95-99% identity (i e , local sequence identity) with the human framework or constant region sequence, allowing, for example, for conservative substitutions, consensus sequence substitutions, germhne substitutions, backmutations, and the like. The introduction of conservative substitutions, consensus sequence substitutions, germhne substitutions, backmutations, and the like, is often refe ⁇ ed to as "optimization" of a humanized antibody or chain
- substantially from a non-human immunoglobulin or antibody or “substantially non- human” means having an immunoglobulin or antibody sequence at least 80-95%, preferably at least 90-95%, more preferably, 96%, 97%, 98%, or 99% identical to that of a non-human organism, e g ,
- co ⁇ esponding region or "corresponding residue” refers to a region or residue on a second amino acid or nucleotide sequence which occupies the same (i e , equivalent) position as a region or residue on a first ammo acid or nucleotide sequence, when the first and second sequences are optimally aligned for compa ⁇ son purposes
- sequence companson typically one sequence acts as a reference sequence, to which test sequences are compared When using a sequence companson algo ⁇ thm, test and reference sequences are input into a computer, subsequence coordinate
- algo ⁇ thm that is suitable for determining percent sequence identity and sequence similanty is the BLAST algo ⁇ thm, which is desc ⁇ bed in Altschul et al , J Mol Biol 215 403 (1990)
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (publicly accessible through the National Institutes of Health NCBI internet server)
- default program parameters can be used to perform the sequence compa ⁇ son, although customized parameters can also be used
- the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 sco ⁇ ng matnx ( «?e Hemkoff& Hen ⁇ koff, /V ⁇ c Natl Acad Sci USA 89 10915 (1989))
- residue positions which are not identical differ by conservative amino acid
- humanized immunoglobulins or antibodies bind antigen with an affinity that is within a factor of three, four, or five of that of the co ⁇ esponding non- humanized antibody
- the nonhumamzed antibody has a binding affinity of 10 9 M '
- humanized antibodies will have a binding affinity of at least 3 x 10 9 M ', 4 x 10 9 M ' or 10 9 M '
- the chain can be described based on its ability to "direct antigen (e g , A ⁇ ) binding"
- a chain is said to "direct antigen binding" when it confers upon an intact immunoglobulin or antibody (or antigen binding fragment thereof) a specific binding property or binding affinity
- a mutation e g , a backmutation
- an “antigen” is an entity (e g , a proteinaceous entity or peptide) to which an antibody specifically binds
- epitopes refers to a site on an antigen to which an immunoglobulin or antibody (or antigen binding fragment thereof) specifically binds
- Epitopes can be formed both from contiguous amino acids or noncontiguous ammo acids j uxtaposed by tertiary folding of a protein
- Epitopes formed from contiguous ammo acids are typically retained on exposure to denatunng solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denatunng solvents
- An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation
- Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2- dimensional nuclear magnetic resonance See, e g , Epitope Mapping Protocols in Methods in Molecular Biology, Vol 66, G E Moms, Ed (1996) Antibodies that recognize the same epitope can be identified in a simple
- such an assay involves the use of pu ⁇ fied antigen bound to a solid surface or cells bea ⁇ ng either of these, an unlabeled test immunoglobulin and a labeled reference immunoglobulin Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin Usually the test immunoglobulin is present in excess Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50-55%, 55-60%, 60-65%, 65-70% 70-75% or more
- An epitope is also recognized by immunologic cells, for example, B cells and/or T cells
- Immunological recognition of an epitope can be determined by in vitro assays that measure antigen-dependent proliferation, as determined by H-thymidine incorporation, by cytokine secretion, by antibody secretion, or by antigen-dependent killing (cytotoxic T lymphocyte assay)
- Exemplary epitopes or antigenic determinants can be found within the human amyloid precursor protein (APP), but are preferably found within the A ⁇ peptide of APP Multiple isoforms of APP exist, for example APP 695 APP 751 and APP 770
- a ⁇ (also referred to herein as beta amyloid peptide and A-beta) peptide is an approximately 4-kDa internal fragment of 39- 43 ammo acids of APP (A ⁇ 39, A ⁇ 40, A ⁇ 41, A ⁇ 42 and A ⁇ 43)
- a ⁇ 40 for example, consists of residues 672-711 of APP and A ⁇ 42 consists of residues 673-713 of APP
- a ⁇ is found in both a "short form", 40 ammo acids in length, and a "long form", ranging from 42-43 ammo acids in length
- Prefe ⁇ ed epitopes or antigenic determinants, as descnbed herein are located within the N-terminus of the A ⁇ peptide and include
- an antibody When an antibody is said to bind to an epitope within specified residues, such as A ⁇ 3-7, what is meant is that the antibody specifically binds to a polypeptide containing the specified residues (i.e., A ⁇ 3-7 in this an example). Such an antibody does not necessarily contact every residue within A ⁇ 3-7. Nor does every single amino acid substitution or deletion with in A ⁇ 3-7 necessarily significantly affect binding affinity.
- a ⁇ 3-7 a polypeptide containing the specified residues
- a ⁇ 3-7 in this an example
- amyloidogenic diseases include, but are not limited to systemic amyloidosis, Alzheimer's disease, mature onset diabetes, Parkinson's disease, Huntington's disease, fronto-temporal dementia, and the prion-related transmissible spongiform encephalopathies (kuru and Creutzfeldt-Jacob disease in humans and scrapie and BSE in sheep and cattle, respectively).
- Different amyloidogenic diseases are defined or characterized by the nature of the polypeptide component of the fibrils deposited. For example, in subjects or patients having Alzheimer's disease, ⁇ -amyloid protein (e.g., wild-type, variant, or truncated ⁇ -amyloid protein) is the characterizing polypeptide component of the amyloid deposit.
- Alzheimer's disease is an example of a “disease characterized by deposits of A ⁇ ” or a “disease associated with deposits of A ⁇ ", e.g., in the brain of a subject or patient.
- the terms " ⁇ -amyloid protein”, “ ⁇ -amyloid peptide”, “ ⁇ -amyloid”, “A ⁇ ” and “A ⁇ peptide” are used interchangeably herein.
- An "immunogenic agent” or “immunogen” is capable of inducing an immunological response against itself on administration to a mammal, optionally in conjunction with an adjuvant.
- treatment is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease.
- terapéuticaally effective dose is defined as an amount sufficient to cure or at least partially arrest the disease and its complications in a patient already suffering from the disease Amounts effective for this use will depend upon the seventy of the infection and the general state of the patient's own immune system
- patient includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment
- soluble or “dissociated” A ⁇ refers to non-aggregating or disaggregated
- a ⁇ polypeptide including monomenc soluble as well as ohgome ⁇ c soluble A ⁇ polypeptide (e g , soluble A ⁇ dimers, t ⁇ mers, and the like)
- “Insoluble” A ⁇ refers to aggregating A ⁇ polypeptide, for example, A ⁇ held together by noncovalent bonds A ⁇ (eg , A ⁇ 42) is believed to aggregate, at least in part, due to the presence of hydrophobic residues at the C-terminus of the peptide (part of the transmembrane domain of APP) Soluble A ⁇ can be found in vivo in biological fluids such as cerebrospmal fluid and/or serum Alternatively, soluble A ⁇ can be prepared by dissolving lyophihzed peptide in neat DMSO with somcation The resulting solution is centrifuged (e g , at 14,000x g, 4°C, 10 minutes) to remove any insoluble particulates
- effector function refers to an activity that resides in the Fc
- effector cell refers to a cell capable of binding to the Fc portion of an antibody (e g , an IgG antibody) typically via an Fc receptor expressed on the surface of the effector cell including, but not limited to, lymphocytes, e g , antigen presenting cells and T cells
- Fc region refers to a C-terminal region of an IgG antibody, in particular, the C-terminal region of the heavy cha ⁇ n(s) of said IgG antibody
- a Fc region is typically defined as spanning from about amino acid residue Cys226 to the carboxyl- terminus of an IGg heavy cha ⁇ n(s)
- Kabat numbering unless otherwise stated, is defined as the numbering of the residues in, e.g., an IgG heavy chain antibody using the EU index as in Kabat et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)), expressly incorporated herein by reference.
- Fc receptor refers to a receptor that binds to the Fc region of an antibody.
- Typical Fc receptors which bind to an Fc region of an antibody include, but are not limited to, receptors of the Fc ⁇ RI, Fc ⁇ REl, and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors.
- Fc receptors are reviewed in Ravetch and Kinet, Annu. Rev. Immunol 9:457- 92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995).
- Immunological and therapeutic reagents of the invention comprise or consist of immunogens or antibodies, or functional or antigen binding fragments thereof, as defined herein.
- the basic antibody structural unit is known to comprise a tetramer of subunits. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa).
- the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
- Light chains are classified as either kappa or lambda and are about 230 residues in length.
- Heavy chains are classified as gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ), or epsilon ( ⁇ ), are about 450-600 residues in length, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
- Both heavy and light chains are folded into domains.
- domain refers to a globular region of a protein, for example, an immunoglobulin or antibody.
- Immunoglobulin or antibody domains include, for example, 3 or four peptide loops stabilized by ⁇ -pleated sheet and an interchain disulfide bond.
- Intact light chains have, for example, two domains (V ⁇ _ and C ) and intact heavy chains have, for example, four or five domains (V H , C H I , C H 2, and
- variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 10 more amino acids.
- variable regions of each light/heavy chain pair form the antibody binding site.
- an intact antibody has two binding sites.
- the two binding sites are the same.
- the chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
- Naturally-occurring chains or recombinantly produced chains can be expressed with a leader sequence which is removed during cellular processing to produce a mature chain.
- Mature chains can also be recombinantly produced having a non-naturally occu ⁇ ing leader sequence, for example, to enhance secretion or alter the processing of a particular chain of interest.
- both light and heavy chains comprise the domains FRl, CDRl, FR2, CDR2,
- FR3 also is refened to in the art as the D/J region of the variable heavy chain and the J region of the variable light chain.
- the assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of
- Chothia et al (hereinafter collectively referred to as "Chothia et al.” and incorporated by reference in their entirety for all purposes).
- Therapeutic agents of the invention include antibodies that specifically bind to A ⁇ or to other components of the amyloid plaque.
- Preferred antibodies are monoclonal antibodies. Some such antibodies bind specifically to the aggregated form of A ⁇ without binding to the soluble form Some bind specifically to the soluble form without binding to the aggregated form Some bind to both aggregated and soluble forms
- Antibodies used in therapeutic methods preferably have an intact constant region or at least sufficient of the constant region to interact with an Fc receptor Preferred antibodies are those efficacious at stimulating Fc-mediated phagocytosis of A ⁇ in plaques
- Human isotype IgGl is preferred because of it having highest affinity of human isotypes for the FcRI receptor on phagocytic cells (e g , on brain resident macrophages or microghal cells)
- Human IgGl is the equivalent of mu ⁇ ne IgG2a, the latter thus suitable for testing in vivo efficacy in animal (e g , mouse) models of Alzheimer's Bispecific Fab fragments
- Monoclonal antibodies bind to a specific epitope withm A ⁇ that can be a conformational or nonconformational epitope
- Preferred monoclonal antibodies bind to an epitope withm residues 1-10 of A ⁇ (with the first N terminal residue of natural A ⁇ designated 1), more preferably to an epitope within residues 3-7 of A ⁇
- multiple monoclonal antibodies having binding specificities to different epitopes are used, for example, an antibody specific for an epitope within residues 3-7 of A ⁇ can be co-admimstered with an antibody specific for an epitope outside of residues 3-7 of A ⁇
- Such antibodies can be administered sequentially or simultaneously
- Antibodies to amyloid components other than A ⁇ can also be used (e g , administered or co-admimstered)
- Epitope specificity of an antibody can be determined, for example, by forming a phage display library in which different members display different subs
- Antibodies that specifically bind to a preferred segment of A ⁇ without binding to other regions of A ⁇ have a number of advantages relative to monoclonal antibodies binding to other regions or polyclonal sera to intact A ⁇
- dosages of antibodies that specifically bind to prefe ⁇ ed segments contain a higher molar dosage of antibodies effective in cleanng amyloid plaques
- antibodies specifically binding to prefe ⁇ ed segments can induce a cleanng response against amyloid deposits without inducing a cleanng response against intact APP polypeptide, thereby reducing the potential side effects
- the present invention features non-human antibodies, for example, antibodies having specificity for the preferred A ⁇ epitopes of the invention
- Such antibodies can be used in formulating va ⁇ ous therapeutic compositions of the invention or, preferably, provide complementanty determining regions for the production of humanized or chime ⁇ c antibodies (descnbed in detail below)
- the production of non- human monoclonal antibodies, e g , mu ⁇ ne, guinea pig, p ⁇ mate, rabbit or rat can be accomplished by, for example, immunizing the animal with A ⁇ A longer polypeptide compnsing A ⁇ or an immunogenic fragment of A ⁇ or anti-idiotypic antibodies to an antibody to A ⁇ can also be used See Harlow & Lane, supra, incorporated by reference for all purposes)
- Such an immunogen can be obtained from a natural source, by peptide synthesis or by recombinant expression
- the immunogen can be administered fused or otherwise complexed with a earner protein, as descnbed below
- the immunogen can
- mice are typically used for making monoclonal antibodies
- Monoclonals can be prepared against a fragment by injecting the fragment or longer form of A ⁇ into a mouse, preparing hybndomas and screening the hyb ⁇ domas for an antibody that specifically binds to A ⁇
- antibodies are screened for binding to a specific region or desired fragment of A ⁇ without binding to other nonoverlapping fragments of A ⁇
- the latter screening can be accomplished by determining binding of an antibody to a collection of deletion mutants of an A ⁇ peptide and determining which deletion mutants bind to the antibody Binding can be assessed, for example, by Western blot or ELISA
- the smallest fragment to show specific binding to the antibody defines the epitope of the antibody
- epitope specificity can be determined by a competition assay is which a test and reference antibody compete for binding to A ⁇ If the test and reference antibodies compete, then they bind to the same epitope or epitopes sufficiently proximal such that binding of one antibody interferes with binding of the
- the present invention also features chimenc and/or humanized antibodies (i e , chimenc and/or humanized immunoglobulins) specific for beta amyloid peptide Chimenc and/or humanized antibodies have the same or similar binding specificity and affinity as a mouse or other nonhuman antibody that provides the starting matenal for construction of a chimenc or humanized antibody
- chimenc antibody refers to an antibody whose light and heavy chain genes have been constructed, typically by genetic engineenng, from immunoglobulin gene segments belonging to different species
- V vanable
- C human constant
- a typical chimenc antibody is thus a hybnd protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody
- humanized antibody refers to an antibody comprising at least one chain compnsing vanable region framework residues substantially from a human antibody chain (refe ⁇ ed to as the acceptor immunoglobulin or antibody) and at least one complementanty determining region substantially from a mouse antibody, (referred to as the donor immunoglobulin or antibody) See, Queen et al , Proc Natl Acad Sci USA 86 10029-10033 (1989), US 5,530,101, US 5,585,089, US 5,693,761, US 5,693,762, Sehck et al , WO 90/07861, and Winter, US 5,225,539 (incorporated by reference m their entirety for all purposes)
- the constant reg ⁇ on(s), if present, are also substantially or entirely from a human immunoglobulin
- the substitution of mouse CDRs into a human vanable domain framework is most likely to result in retention of their co ⁇ ect spatial onentation if the human vanable domain framework adopts the same or similar conformation to the mouse va ⁇ able framework from which the CDRs originated. This is achieved by obtaining the human vanable domains from human antibodies whose framework sequences exhibit a high degree of sequence identity with the munne va ⁇ able framework domains from which the CDRs were denved
- the heavy and light chain vanable framework regions can be denved from the same or different human antibody sequences
- the human antibody sequences can be the sequences of naturally occumng human antibodies or can be consensus sequences of several human antibodies See Kettleborough et al , Protein Engineering 4 773 (1991), Kolbinger et al , Protein Engineering 6 971 (1993) and Carter et al , WO 92/22653
- the next step is to determine which, if any, residues from these components should be substituted to optimize the properties of the resulting humanized antibody
- substitution of human amino acid residues with munne should be minimized, because introduction of mu ⁇ ne residues increases the ⁇ sk of the antibody eliciting a human-anti-mouse-antibody (HAMA) response in humans
- HAMA human-anti-mouse-antibody
- Art-recognized methods of determining immune response can be performed to momtor a HAMA response in a particular patient or du ⁇ ng clinical tnals
- Patients administered humanized antibodies can be given an immunogenicity assessment at the beginning and throughout the administration of said therapy
- the HAMA response is measured, for example, by detecting antibodies to the humanized therapeutic reagent, in serum samples from the patient using a method known to one in the art, including surface plasmon resonance technology (BIACORE) and/or solid-phase ELISA analysis
- Certain amino acids from the human va ⁇ able region framework residues are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen
- the unnatural juxtaposition of mu ⁇ ne CDR regions with human va ⁇ able framework region can result in unnatural conformational restraints, which, unless corrected by substitution of certain amino acid residues, lead to loss of binding affinity
- Residues which "noncovalently bind antigen directly" include amino acids in positions in framework regions which are have a good probability of directly interacting with amino acids on the antigen according to established chemical forces, for example, by hydrogen bonding, Van der Waals forces, hydrophobic interactions, and the like
- CDR and framework regions are as defined by Kabat et al or Chothia et al , supra
- framework residues as defined by Kabat et al , supra, constitute structural loop residues as defined by Chothia et al , supra
- the ammo acids present in the mouse antibody may be selected for substitution into the humanized antibody
- Residues which are "adjacent to a CDR region" include amino acid residues in positions immediately adjacent to one or more of the CDRs in the p ⁇ mary sequence of the humanized immunoglobulin chain, for example, in positions immediately adjacent to a CDR as defined by Kabat, or a CDR as defined by Chothia (See e g , Chothia and Lesk JMB 196 901 (1987))
- These amino acids are particularly likely to interact with the amino acids in the CDRs and, if chosen from the acceptor, to distort the donor CDRs and reduce affinity
- the adjacent ammo acids may interact directly with the antigen (Amit
- Residues that "otherwise interact with a CDR region” include those that are determined by secondary structural analysis to be in a spatial onentation sufficient to affect a CDR region.
- residues that "otherwise interact with a CDR region” are identified by analyzing a three-dimensional model of the donor immunoglobulin (e g , .
- the donor immunoglobulin ammo acid rather than the acceptor immunoglobulin ammo acid may be selected Amino acids according to this criterion will generally have a side chain atom within about 3 angstrom units (A) of some atom in the CDRs and must contain an atom that could interact with the CDR atoms according to established chemical forces, such as those listed above
- the 3 A is measured between their nuclei, but for atoms that do not form a bond, the 3 A is measured between their Van der Waals surfaces Hence, in the latter case, the nuclei must be within about 6 A (3 A plus the sum of the Van der Waals radii) for the atoms to be considered capable of interacting In many cases the nuclei will be from 4 or 5 to 6 A apart
- CDRs may be identified in yet another way
- the solvent accessible surface area of each framework amino acid is calculated in two ways (1) in the intact antibody, and (2) in a hypothetical molecule consisting of the antibody with its CDRs removed A significant difference between these numbers of about 10 square angstroms or more shows that access of the framework amino acid to solvent is at least partly blocked by the CDRs, and therefore that the amino acid is making contact with the CDRs
- Solvent accessible surface area of an amino acid may be calculated based on a three-dimensional model of an antibody, using algonthms known in the art (e , Connolly, J Appl Cryst 16 548 (1983) and Lee and Richards, J Mol Biol 55 379 (1971), both of which are incorporated herein by reference)
- Framework amino acids may also occasionally interact with the CDRs indirectly, by affecting the conformation of another framework amino acid that in turn contacts the CDRs
- the ammo acids at several positions in the framework are known to be capable of interacting with the CDRs m many antibodies
- amino acids at positions 35 in the light chain and 93 and 103 in the heavy chain are also likely to interact with the CDRs At all these numbered positions, choice of the donor amino acid rather than the acceptor ammo acid (when they differ) to be in the humanized immunoglobulin is prefe ⁇ ed On the other hand, certain residues capable of interacting with the CDR region, such as the first 5 amino acids of the light chain, may sometimes be chosen from the acceptor immunoglobulin without loss of affinity in the humanized immunoglobulin
- Residues which "participate in the VL-VH interface” or "packing residues” include those residues at the interface between VL and VH as defined, for example, by Novotny and Haber, Proc Natl Acad Sci USA, 82 4592-66 (1985) or Chothia et al, supra Generally, unusual packing residues should be retained in the humanized antibody if they differ from those in the human frameworks
- one or more of the ammo acids fulfilling the above c ⁇ te ⁇ a is substituted in some embodiments, all or most of the amino acids fulfilling the above c ⁇ tena are substituted Occasionally, there is some ambiguity about whether a particular amino acid meets the above c ⁇ te ⁇ a, and alternative va ⁇ ant immunoglobulins are produced, one of which has that particular substitution, the other of which does not Alternative vanant immunoglobulins so produced can be tested in any of the assays descnbed herein for the desired activity, and the preferred immunoglobulin selected
- CDR regions in humanized antibodies are substantially identical, and more usually, identical to the corresponding CDR regions of the donor antibody
- conservative substitutions is intended combinations such as gly, ala, val, lie, leu, asp, glu, asn, gin, ser, thr, lys, arg, and phe, tyr
- Additional candidates for substitution are acceptor human framework amino acids that are unusual or "rare" for a human immunoglobulin at that position
- These amino acids can be substituted with amino acids from the equivalent position of the mouse donor antibody or from the equivalent positions of more typical human immunoglobulins
- substitution may be desirable when the ammo acid in a human framework region of the acceptor immunoglobulin is rare for that position and the co ⁇ esponding amino acid in the donor immunoglobulin is common for that position in human immunoglobulin sequence
- IR indicates an amino acid occurring at that position in less than about 20% but usually less than about 10% of sequences in a representative sample of sequences
- common indicates an amino acid occur ⁇ ng in more than about 25% but usually more than about 50% of sequences in a representative sample
- all human light and heavy chain variable region sequences are respectively grouped into "subgroups" of sequences that are especially homologous to each other and have the same amino acids at certain cntical positions (Kabat et al , supra)
- Additional candidates for substitution are acceptor human framework amino acids that would be identified as part of a CDR region under the alternative definition proposed by Chothia et al , supra Additional candidates for substitution are acceptor human framework amino acids that would be identified as part of a CDR region under the AbM and/or contact definitions
- Additional candidates for substitution are acceptor framework residues that co ⁇ espond to a rare or unusual donor framework residue
- Rare or unusual donor framework residues are those that are rare or unusual (as defined herein) for mu ⁇ ne antibodies at that position
- the subgroup can be detennined according to Kabat and residue positions identified which differ from the consensus These donor specific differences may point to somatic mutations in the mu ⁇ ne sequence which enhance activity Unusual residues that are predicted to affect binding are retained, whereas residues predicted to be unimportant for binding can be substituted
- Additional candidates for substitution are non-germhne residues occurring in an acceptor framework region For example, when an acceptor antibody chain (i e , a human antibody chain shanng significant sequence identity with the donor antibody chain) is aligned to a germhne antibody chain (likewise shanng significant sequence identity with the donor chain), residues not matching between acceptor chain framework and the germhne chain framework can be substituted with co ⁇ esponding residues from the germhne sequence
- the framework regions of humanized immunoglobulins are usually substantially identical, and more usually, identical to the framework regions of the human antibodies from which they were denved
- many of the amino acids in the framework region make little or no direct cont ⁇ bution to the specificity or affinity of an antibody
- many individual conservative substitutions of framework residues can be tolerated without appreciable change of the specificity or affinity of the resulting humanized immunoglobulin
- the va ⁇ able framework region of the humanized immunoglobulin shares at least 85% sequence identity to a human va ⁇ able framework region sequence or consensus of such sequences
- the vanable framework region of the humanized immunoglobulin shares at least 90%, preferably 95%, more preferably 96%, 97%, 98% or 99% sequence identity to a human variable framework region sequence or consensus of such sequences. In general, however, such substitutions are undesirable.
- the humanized antibodies preferably exhibit a specific binding affinity for antigen of at least 10 7 , 10 8 , 10 9 or 10 10 M "1 .
- the upper limit of binding affinity of the humanized antibodies for antigen is within a factor of three, four or five of that of the donor immunoglobulin.
- the lower limit of binding affinity is also within a factor of three, four or five of that of donor immunoglobulin.
- the binding affinity can be compared to that of a humanized antibody having no substitutions (e.g., an antibody having donor CDRs and acceptor FRs, but no FR substitutions).
- the binding of the optimized antibody (with substitutions) is preferably at least two- to three-fold greater, or three- to four-fold greater, than that of the unsubstituted antibody.
- activity of the various antibodies can be determined, for example, by BIACORE (i.e., surface plasmon resonance using unlabelled reagents) or competitive binding assays.
- a prefe ⁇ ed embodiment of the present invention features a humanized antibody to the N-terminus of A ⁇ , in particular, for use in the therapeutic and/or diagnostic methodologies described herein.
- a particularly preferred starting material for production of humanized antibodies is 12B4.
- 12B4 is specific for the N-terminus of A ⁇ and has been shown to mediate phagocytosis (e.g., induce phagocytosis) of amyloid plaque.
- the cloning and sequencing of cDNA encoding the 12B4 antibody heavy and light chain variable regions is described in Example I.
- Suitable human acceptor antibody sequences are identified by computer comparisons of the amino acid sequences of the mouse variable regions with the sequences of known human antibodies. The comparison is performed separately for heavy and light chains but the principles are similar for each.
- variable domains from human antibodies whose framework sequences exhibit a high degree of sequence identity with the murine VL and VH framework regions were identified by query of the Kabat Database using NCBI BLAST (publicly accessible through the National Institutes of Health NCBI internet server) with the respective murine framework sequences.
- acceptor sequences sharing greater that 50% sequence identity with murine donor sequences are selected.
- acceptor antibody sequences sharing 60%, 70%, 80%, 90% or more are selected.
- a computer comparison of 12B4 revealed that the 12B4 light chain shows the greatest sequence identity to human light chains of subtype kappa II, and that the 12B4 heavy chain shows greatest sequence identity to human heavy chains of subtype II, as defined by Kabat et al., supra.
- light and heavy human framework regions are preferably derived from human antibodies of these subtypes, of from consensus sequences of such subtypes.
- the prefe ⁇ ed light chain human variable regions showing greatest sequence identity to the conesponding region from 12B4 are from an antibody having Kabat ED Number 005036.
- the prefened heavy chain human variable regions showing greatest sequence identity to the co ⁇ esponding region from 12B4 are from an antibody having Kabat ED Number 000333, an antibody having Genbank Accession No.
- Residues are next selected for substitution, as follows. When an amino acid differs between a 12B4 variable framework region and an equivalent human variable framework region, the human framework amino acid should usually be substituted by the equivalent mouse amino acid if it is reasonably expected that the amino acid: (1) noncovalently binds antigen directly,
- Example V Computer modeling of the 12B4 antibody heavy and light chain variable regions, and humanization of the 12B4 antibody is described in Example V. Briefly, a three-dimensional model is generated based on the closest solved murine antibody structures for the heavy and light chains. The model is further refined by a series of energy minimization steps to relieve unfavorable atomic contacts and optimize electrostatic and van der Walls interactions.
- Three-dimensional structural information for the antibodies described herein is publicly available, for example, from the Research Collaboratory for Structural Bioinformatics' Protein Data Bank (PDB).
- PDB is freely accessible via the World Wide Web internet and is descnbed by Berman et al (2000) Nucleic Acids Research, 28 235
- Computer modeling allows for the identification of CDR-interacting residues
- the computer model of the structure of 12B4 can in turn serve as a starting point for predicting the three-dimensional structure of an antibody containing the 12B4 complementa ⁇ ty determining regions substituted in human framework structures Additional models can be constructed representing the structure as further amino acid substitutions are introduced
- the humanized antibodies of the present invention will usually contain a substitution of a human light chain framework residue with a conesponding 12B4 residue in at least 1, 2, 3 or more of the chosen positions
- the humanized antibodies also usually contain a substitution of a human heavy chain framework residue with a conesponding 12B4 residue in at least 1, 2, 3 or more of the chosen positions Occasionally, however, there is some ambiguity about whether a particular amino acid meets the above cntena, and alternative vanant immunoglobulins are produced, one of which has that particular substitution, the other of which does not En instances where substitution with a munne residue would introduce a residue that is rare in human immunoglobulins at a particular position, it may be desirable to test the antibody for activity with or without the particular substitution If activity (e g , binding affinity and/or binding specificity) is about the same with or without the substitution, the antibody without substitution may be prefened, as it
- Table 1 summa ⁇ zes the sequence analysis of the 12B4 VH and VL regions Additional mouse and human structures that can be used for computer modeling of the 12B4 antibody and additional human antibodies are set forth as well as germhne sequences that can be used in selecting amino acid substitutions Rare mouse residues are also set forth in Table 1 Rare mouse residues are identified by compa ⁇ ng the donor VL and/or VH sequences with the sequences of other members of the subgroup to which the donor VL and/or VH sequences belong (according to Kabat) and identifying the residue positions which differ from the consensus These donor specific differences may point to somatic mutations which enhance activity Unusual or rare residues close to the binding site may possibly contact the antigen, making it desirable to retain the mouse residue However, if the unusual mouse residue is not important for binding, use of the conesponding acceptor residue is prefened as the mouse residue may create immunogenic neoepitopes in the humanized antibody In the situation where an unusual residue in the donor sequence is actually a common residue in the corresponding acceptor
- Kabat ED sequences referenced herein are publicly available, for example, from the Northwestern University Biomedical Engineering Department's Kabat Database of Sequences of Proteins of Immunological Interest. Three-dimensional structural information for antibodies described herein is publicly available, for example, from the Research Collaboratory for Structural Bioinformatics' Protein Data Bank (PDB).
- PDB is freely accessible via the World Wide Web internet and is described by Berman et al. (2000) Nucleic Acids Research, p235-242.
- Germline gene sequences referenced herein are publicly available, for example, from the National Center for Biotechnology Information (NCBI) database of sequences in collections of Igh, lg kappa and lg lambda germline V genes (as a division of the National Library of Medicine (NLM) at the National Institutes of Health (NEH)). Homology searching of the NCBI "lg Germline Genes" database is provided by IgG BLASTTM.
- NCBI National Center for Biotechnology Information
- a humanized antibody of the present invention contains (1) a light chain comp ⁇ sing a va ⁇ able domain comp ⁇ sing munne 12B4 VL CDRs and a human acceptor framework, the framework having at least one, residue substituted with the conesponding 12B4 residue and (n) a heavy chain compnsing 12B4 VH CDRs and a human acceptor framework, the framework having at least one, preferably two, three, four, five, six, seven, eight, or nine residues substituted with the co ⁇ esponding 12B4 residue, and, optionally, at least one, preferably two or three residues substituted with a co ⁇ esponding human germhne residue
- a humanized antibody of the present invention has structural features, as descnbed herein, and further has at least one
- binds soluble A ⁇ (2) binds aggregated A ⁇ 1 -42 (e g , as determined by ELISA), (3) binds A ⁇ in plaques (e g , staining of AD and/or PDAPP plaques), (4) binds A ⁇ with two- to three- fold higher binding affinity as compared to chime ⁇ c 12B4 (e g , 12B4 having munne vanable region sequences and human constant region sequences), (5) mediates phagocytosis of A ⁇ (e g , in an ex vivo phagocytosis assay, as described herein), and (6) crosses the blood-brain barner (e , demonstrates short-term brain localization, for example, in a PDAPP animal model, as descnbed herein)
- a humanized antibody of the present invention has structural features, as descnbed herein, binds A ⁇ in a manner or with an affinity sufficient to elicit at least one of the following in vivo effects (1) reduce A ⁇ plaque burden, (2) prevent plaque formation, (3) reduce levels of soluble A ⁇ , (4) reduce the neuntic pathology associated with an amyloidogenic disorder, (5) lessen or ameliorate at least one physiological symptom associated with an amyloidogenic disorder, and/or (6) improve cognitive function
- a humanized antibody of the present invention has structural features, as descnbed herein, and specifically binds to an epitope compnsing residues 3-7 of A ⁇
- a humanized antibody of the present invention has structural features, as descnbed herein, binds to an N-terminal epitope within A ⁇ (e g , binds to an epitope within amino acids 3-7 of A ⁇ ), and is capable of reducing (1) A ⁇ peptide levels, (2) A ⁇ plaque burden, and (3) the neuntic burden or neu ⁇ tic dystrophy associated with an amyloidogenic disorder
- Activities descnbed above can be detennined utilizing any one of a variety of assays descnbed herein or in the art (e g , binding assays, phagocytosis assays, etc ) Activities can be assayed either in vivo (e g , using labeled assay components and/or imaging techniques) or in vitro (e g , using samples or specimens denved from a subject) Activities can be assayed either directly or indirectly In certain prefened embodiments, neurological endpoints (e g , amyloid burden, neu ⁇ tic burden, etc) are assayed Such endpoints can be assayed in living subjects (e g , in animal models of Alzheimer's disease or in human subjects, for example, undergoing immunotherapy) using non-invasive detection methodologies Alternatively, such endpoints can be assayed in subjects post mortem Assaying such endpoints in animal models and/or in human subjects post mortem is useful in assessing the effectiveness of vanous agents (
- a vanety of nucleic acid sequences will encode each immunoglobulin amino acid sequence
- the desired nucleic acid sequences can be produced by de novo solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared vanant of the desired polynucleotide
- Ohgonucleotide-mediated mutagenesis is a prefened method for prepanng substitution, deletion and insertion vanants of target polypeptide DNA See Adelman et al , DNA 2 183 (1983) Bnefly, the target polypeptide DNA is altered by hybndizing an oligonucleotide encoding the desired mutation to a single-stranded DNA template After hybndization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that incorporates the oligonucleot
- the vanable segments of antibodies produced as described supra are typically linked to at least a portion of an immunoglobulin constant region (Fc region), typically that of a human immunoglobulin Human constant region DNA sequences can be isolated in accordance with well known procedures from a vanety of human cells, but preferably immortalized B cells (see Kabat et al , supra, and Liu et al , W087/02671) (each of which is incorporated by reference in its entirety for all purposes) Ordinanly, the antibody will contain both light chain and heavy chain constant regions
- the heavy chain constant region usually includes CHI, hinge, CH2, CH3, and CH4 regions
- the antibodies descnbed herein include antibodies having all types of constant regions, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGl, lgG2, IgG3 and IgG4 When it is desired that the antibody (e g , the heavy and light chain vanable regions of chime ⁇ c or humanized
- Chimenc and humanized antibodies are typically produced by recombinant expression
- Nucleic acids encoding light and heavy chain vanable regions, optionally linked to constant regions, are inserted into expression vectors
- the light and heavy chains can be cloned in the same or different expression vectors
- the DNA segments encoding immunoglobulin chains are operably linked to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides
- Expression control sequences include, but are not limited to, promoters (e , naturally- associated or heterologous promoters), signal sequences, enhancer elements, and transcnption termination sequences
- the expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells Once the vector has been incorporated into the appropnate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and the collection and pu ⁇ fication of the crossreacting antibodies
- expression vectors are typically rep cable in the host organisms either as episomes or as an integral part of the host chromosomal DNA
- expression vectors contain selection markers (e , ampicilhn-resistance, hygromycin- resistance, tetracycline resistance, kanamycin resistance or neomycin resistance) to permit detection of those cells transformed with the desired DNA sequences (see, e g , Itakura et al , US Patent 4,704,362)
- E coli is one prokaryotic host particularly useful for cloning the polynucleotides (e g , DNA sequences) of the present invention
- Other microbial hosts suitable for use include bacilli, such as Bacillus subtihs, and other enterobacte ⁇ aceae, such as Salmonella, Serratia, and vanous Pseudomonas species
- bacilli such as Bacillus subtihs
- enterobacte ⁇ aceae such as Salmonella, Serratia, and vanous Pseudomonas species
- expression vectors which will typically contain expression control sequences compatible with the host cell (e g , an on gin of replication)
- any number of a vanety of well-known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda
- Saccharomyces is a prefe ⁇ ed yeast host, with suitable vectors having expression control sequences (e g , promoters), an ongin of replication, termination sequences and the like as desired Typical promoters include 3-phosphoglycerate kinase and other glycolytic enzymes
- Typical yeast promoters include 3-phosphoglycerate kinase and other glycolytic enzymes
- Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes responsible for maltose and galactose utilization
- mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (e g , polynucleotides encoding immunoglobulins or fragments thereof) See Winnacker, From Genes to Clones, VCH Publishers, N Y , N Y (1987)
- Eukaryotic cells are actually prefe ⁇ ed, because a number of suitable host cell lines capable of secreting heterologous proteins (e g , intact immunoglobulins) have been developed in the art, and include CHO cell lines, vanous Cos cell lines, HeLa cells, preferably, myeloma cell lines, or transformed B-cells or hybndomas
- the cells are nonhuman Expression vectors for these cells can include expression control sequences, such as an o ⁇ gin of replication, a promoter, and an enhancer (Queen et al , Immunol Rev 89 49 (1986)), and necessary processing information sites, such as
- transgenes can be incorporated in transgenes for introduction into the genome of a transgenic animal and subsequent expression in the milk of the transgenic animal (see, e g , Deboer et al , US 5,741,957, Rosen, US 5,304,489, and Meade et al , US 5,849,992)
- Suitable transgenes include coding sequences for light and/or heavy chains in operable linkage with a promoter and enhancer from a mammary gland specific gene, such as casein or beta lactoglobuhn
- the vectors containing the polynucleotide sequences of interest e g , the heavy and light chain encoding sequences and expression control sequences
- the vectors When heavy and light chains are cloned on separate expression vectors, the vectors are co-transfected to obtain expression and assembly of intact immunoglobulins Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention can be punfied according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, HPLC punfication, gel electrophoresis and the like (see generally Scopes, Protein Pu ⁇ fication (Spnnger- Verlag, N Y , (1982)) Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are prefened, and 98 to 99% or more homogeneity most prefened, for pharmaceutical uses
- fragments of non-human, and/or chime ⁇ c antibodies are provided in another embodiment, fragments of humanized antibodies are provided Typically, these fragments exhibit specific binding to antigen with an affinity of at least 10 7 , and more typically 10 8 or 10 9 M ' Humanized antibody fragments include separate heavy chains, light chains, Fab, Fab', F(ab')2, Fabc, and Fv Fragments are produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins
- PBS of polyclonal anti-A ⁇ or specific anti-A ⁇ monoclonal antibodies All antibody preparations are pu ⁇ fied to have low endotoxin levels
- Monoclonals can be prepared against a fragment by injecting the fragment or longer form of A ⁇ into a mouse, prepanng hybndomas and screening the hyb ⁇ domas for an antibody that specifically binds to a desired fragment of A ⁇ without binding to other nonoverlapping fragments of
- mice are injected intrape ⁇ toneally as needed over a 4 month pe ⁇ od to maintain a circulating antibody concentration measured by ELISA titer of greater than 1/1000 defined by ELISA to A ⁇ 42 or other immunogen Titers are monitored and mice are euthanized at the end of 6 months of injections Histochemistry, A ⁇ levels and toxicology are performed post mortem Ten mice are used per group 8 Screening Antibodies for Clearing Activity
- the invention also provides methods of screening an antibody for activity in cleanng an amyloid deposit or any other antigen, or associated biological entity, for which cleanng activity is desired
- a tissue sample from a brain of a patient with Alzheimer's disease or an animal model having charactenstic Alzheimer's pathology is contacted with phagocytic cells beanng an Fc receptor, such as microghal cells, and the antibody under test in a medium in vitro
- the phagocytic cells can be a p ⁇ mary culture or a cell line, and can be of munne (e , BV-2 or C8-B4 cells) or human ongin (e , THP-1 cells)
- the components are combined on a microscope slide to facilitate microscopic monitonng
- multiple reactions are performed in parallel in the wells of a microtiter dish En such a format, a separate miniature microscope slide can be mounted in the separate wells, or a nonmicroscopic detection format, such as
- Analogous methods can be used to screen antibodies for activity in cleanng other types of biological entities
- the assay can be used to detect cleanng activity against virtually any kind of biological entity
- the biological entity has some role in human or animal disease
- the biological entity can be provided as a tissue sample or in isolated form If provided as a tissue sample, the tissue sample is preferably unfixed to allow ready access to components of the tissue sample and to avoid perturbing the conformation of the components incidental to fixing
- tissue samples that can be tested in this assay include cancerous tissue, precancerous tissue, tissue contaimng benign growths such as warts or moles, tissue infected with pathogenic microorganisms, tissue infiltrated with inflammatory cells, tissue beanng pathological mat ⁇ ces between cells (e g , fibnnous pe ⁇ carditis), tissue beanng abenant antigens, and scar tissue
- isolated biological entities that can be used include A ⁇ , viral antigens or viruses, proteoglycans, antigens of other pathogenic microorganisms, tumor
- the effector function of an antibody resides in the constant or Fc region of the molecule which can mediate binding to vanous effector molecules, e g , complement proteins or Fc receptors
- the binding of complement to the Fc region is important, for example, in the opsonization and lysis of cell pathogens and the activation of inflammatory responses
- the binding of antibody to Fc receptors for example, on the surface of effector cells can tngger a number of important and diverse biological responses including, for example, engulfrnent and destruction of antibody-coated pathogens or particles, clearance of immune complexes, lysis of antibody-coated target cells by killer cells (i e , antibody-dependent cell-mediated cytotoxicity, or ADCC), release of inflammatory mediators, placental transfer of antibodies
- the above-mentioned immune functions may be desirable By alte ⁇ ng the Fc region of the antibody, vanous aspects of the effector function of the molecule, including enhancing or suppressing vanous reactions of the immune system, with beneficial effects in diagnosis and therapy, are achieved
- the antibodies of the invention can be produced which react only with certain types of Fc receptors, for example, the antibodies of the invention can be modified to bind to only certain Fc receptors, or if desired, lack Fc receptor binding entirely, by deletion or alteration of the Fc receptor binding site located in the Fc region of the antibody
- Other desirable alterations of the Fc region of an antibody of the invention are cataloged below Typically the Kabat numbenng system is used to indicate which amino acid res ⁇ due(s) of the Fc region (eg , of an IgG antibody) are altered (e g , by ammo acid substitution) in order to achieve a desired change in effector function
- the numbenng system is also employed to compare antibodies across species such that a desired effector function observed in, for example, a mouse antibody, can then be systematically engineered into a human, humanized, or chime ⁇ c antibody of the invention For example, it has been observed that antibodies (e , IgG antibodies) can be grouped into those found
- the antibodies of the invention can also have an altered Fc region with altered binding affinity for Fc ⁇ RI as compared with the unmodified antibody.
- Such an antibody conveniently has a modification at amino acid residue 234, 235, 236, or 237.
- Affinity for other Fc receptors can be altered by a similar approach, for controlling the immune response in different ways.
- the lytic properties of IgG antibodies following binding of the Cl component of complement can be altered.
- the first component of the complement system, Cl comprises three proteins known as Clq, Clr and Cls which bind tightly together. It has been shown that Clq is responsible for binding of the three protein complex to an antibody.
- the Clq binding activity of an antibody can be altered by providing an antibody with an altered CH 2 domain in which at least one of the amino acid residues 318, 320, and 322 of the heavy chain has been changed to a residue having a different side chain.
- the numbering of the residues in the heavy chain is that of the EU index (see Kabat et al., supra).
- Other suitable alterations for altering, e.g., reducing or abolishing specific Clq-binding to an antibody include changing any one of residues 318 (Glu), 320 (Lys) and 322 (Lys), to Ala.
- the invention also provides an antibody having an altered effector function wherein the antibody has a modified hinge region.
- the modified hinge region may comprise a complete hinge region derived from an antibody of different antibody class or subclass from that of the CHI domain.
- the constant domain (CHI) of a class IgG antibody can be attached to a hinge region of a class IgG4 antibody.
- the new hinge region may comprise part of a natural hinge or a repeating unit in which each unit in the repeat is derived from a natural hinge region.
- the natural hinge region is altered by converting one or more cysteine residues into a neutral residue, such as alanine, or by converting suitably placed residues into cysteine residues. Such alterations are canied out using art recognized protein chemistry and, preferably, genetic engineering techniques, as described herein.
- the number of cysteine residues in the hinge region of the antibody is reduced, for example, to one cysteine residue.
- This modification has the advantage of facilitating the assembly of the antibody, for example, bispecific antibody molecules and antibody molecules wherein the Fc portion has been replaced by an effector or reporter molecule, since it is only necessary to form a single disulfide bond.
- This modification also provides a specific target for attaching the hinge region either to another hinge region or to an effector or reporter molecule, either directly or indirectly, for example, by chemical means.
- the number of cysteine residues in the hinge region of the antibody is increased, for example, at least one more than the number of normally occurring cysteine residues. Increasing the number of cysteine residues can be used to stabilize the interactions between adjacent hinges. Another advantage of this modification is that it facilitates the use of cysteine thiol groups for attaching effector or reporter molecules to the altered antibody, for example, a radiolabel. Accordingly, the invention provides for an exchange of hinge regions between antibody classes, in particular, IgG classes, and or an increase or decrease in the number of cysteine residues in the hinge region in order to achieve an altered effector function (see for example U.S. Patent No. 5,677,425 which is expressly incorporated herein). A determination of altered antibody effector function is made using the assays described herein or other art recognized techniques.
- the resultant antibody can be subjected to one or more assays to evaluate any change in biological activity compared to the starting antibody.
- the ability of the antibody with an altered Fc region to bind complement or Fc receptors can be assessed using the assays disclosed herein as well as any art recognized assay.
- Production of the antibodies of the invention is carried out by any suitable technique including techniques described herein as well as techniques known to those skilled in the art.
- an appropriate protein sequence e.g. forming part of or all of a relevant constant domain, e.g., Fc region, i.e., CH2, and or CH3 domain(s), of an antibody, and include appropriately altered residue(s) can be synthesized and then chemically joined into the appropriate place in an antibody molecule.
- genetic engineering techniques are used for producing an altered antibody.
- Preferred techniques include, for example, preparing suitable primers for use in polymerase chain reaction (PCR) such that a DNA sequence which encodes at least part of an IgG heavy chain, e.g., an Fc or constant region (e.g., CH2, and/or CH3) is altered, at one or more residues.
- PCR polymerase chain reaction
- the segment can then be operably linked to the remaining portion of the antibody, e.g., the variable region of the antibody and required regulatory elements for expression in a cell.
- the present invention also includes vectors used to transform the cell line, vectors used in producing the transforming vectors, cell lines transformed with the transforming vectors, cell lines transformed with preparative vectors, and methods for their production
- the cell line which is transformed to produce the antibody with an altered Fc region is an immortalized mammalian cell line (e g , CHO cell)
- the cell line used to produce the antibody with an altered Fc region is preferably a mammalian cell line
- any other suitable cell line such as a bactenal cell line or a yeast cell line, may alternatively be used
- nucleic acids encoding antibodies and their component chains used for passive immunization can be DNA or RNA
- a nucleic acid segment encoding an immunogen is typically linked to regulatory elements, such as a promoter and enhancer, that allow expression of the DNA segment in the intended target cells of a patient
- regulatory elements such as a promoter and enhancer
- promoter and enhancer elements from light or heavy chain immunoglobulin genes or the CMV major intermediate early promoter and enhancer are suitable to direct expression
- the linked regulatory elements and coding sequences are often cloned into a vector For administration of double-chain antibodies, the two chains can be cloned in the same or separate vectors
- a number of viral vector systems are available including retroviral systems (see, e g , Lawne and Tumin, Cur Opin Genet Develop 3 102-109 (1993)), adenoviral vectors (see, e g , Bett et al , J Virol 67 5911 (1993)), adeno-associated virus vectors (see, e , Zhou et al , J Exp Med 179 1867 (1994)), viral vectors from the pox family including vaccinia virus and the avian pox viruses, viral vectors from the alpha virus genus such as those denved from Smdbis and Semhki Forest Viruses (see, e g , Dubensky et al , J Virol 70 508 (1996)), Venezuelan equine encephalitis virus (see Johnston et al , US 5,643,576) and rhabdoviruses, such as vesicular stomatitis virus (see Rose, 6,168,
- DNA encoding an immunogen can be packaged into liposomes Suitable hpids and related analogs are descnbed by Eppstein et al , US 5,208,036, Feigner et al , US 5,264,618, Rose, US 5,279,833, and Epand et al , US 5,283,185
- Vectors and DNA encoding an immunogen can also be adsorbed to or associated with particulate earners, examples of which include polymethyl methacrylate polymers and polylactides and poly (lactide-co-glycohdes), see, e g , McGee et al , J Micro Encap (1996)
- Gene therapy vectors or naked polypeptides (e , DNA) can be delivered in vivo by administration to an individual patient, typically by systemic administration (e g , intravenous, intrapentoneal, nasal, gast ⁇ c, intradermal, intramuscular, subdermal, or mtracramal infusion) or topic
- systemic administration
- the present invention is directed inter aha to treatment of Alzheimer's and other amyloidogenic diseases by administration of therapeutic immunological reagents (e g , humanized immunoglobulins) to specific epitopes within A ⁇ to a patient under conditions that generate a beneficial therapeutic response in a patient (e g , induction of phagocytosis of A ⁇ , reduction of plaque burden, inhibition of plaque formation, reduction of neu ⁇ tic dystrophy, improving cognitive function, and/or reversing, treating or preventing cognitive decline) in the patient, for example, for the prevention or treatment of an amyloidogenic disease
- the invention is also directed to use of the disclosed immunological reagents (e , humanized immunoglobulins) in the manufacture of a medicament for the treatment or prevention of an amyloidogenic disease
- the invention provides methods of preventing or treating a disease associated with amyloid deposits of A ⁇ in the brain of a patient
- diseases include Alzheimer's disease, Down's syndrome and cognitive impairment The latter can occur with or without other charactenstics of an amyloidogenic disease
- Some methods of the invention entail administenng an effective dosage of an antibody that specifically binds to a component of an amyloid deposit to the patient Such methods are particularly useful for preventing or treating Alzheimer's disease in human patients
- Exemplary methods entail administenng an effective dosage of an antibody that binds to A ⁇
- Prefened methods entail administenng an effective dosage of an antibody that specifically binds to an epitope within residues 1-10 of A ⁇ , for example, antibodies that specifically bind to an epitope within residues 1-3 of A ⁇ , antibodies that specifically bind to an epitope withm residues 1-4 of A ⁇ , antibodies that specifically bind to an epitope within residues 1-5 of A ⁇ , antibodies that specifically bind to an epitope within residues
- the invention features administering antibodies that bind to an amyloid deposit in the patient and induce a cleanng response against the amyloid deposit
- a cleanng response can be effected by Fc receptor mediated phagocytosis
- agents of the invention are typically substantially pure from undesired contaminant This means that an agent is typically at least about 50% w/w (weight/weight) pu ⁇ ty, as well as being substantially free from interfe ⁇ ng proteins and contaminants Sometimes the agents are at least about 80% w/w and, more preferably at least 90 or about 95% w/w punty However, using conventional protein pu ⁇ fication techniques, homogeneous peptides of at least 99% w/w can be obtained
- the methods can be used on both asymptomatic patients and those cunently showing symptoms of disease
- the antibodies used in such methods can be human, humanized, chime ⁇ c or nonhuman antibodies, or fragments thereof (e g , antigen binding fragments) and can be monoclonal or polyclonal, as descnbed herein
- the invention features administenng antibodies prepared from a human immunized with A ⁇ peptide, which human can be the patient to be treated with antibody
- the invention features administenng an antibody with a pharmaceutical earner as a pharmaceutical composition
- the antibody can be administered to a patient by administenng a polynucleotide encoding at least one antibody chain
- the polynucleotide is expressed to produce the antibody chain in the patient
- the polynucleotide encodes heavy and light chains of the antibody
- the polynucleotide is expressed to produce the heavy and light chains in the patient
- the patient is monitored for level of administered antibody in the blood of the patient
- the invention thus fulfills a longstanding need for therapeutic regimes for preventing or ameliorating the neuropathology and, in some patients, the cognitive impairment associated with Alzheimer's disease A.
- Patients amenable to treatment include individuals at risk of disease but not showing symptoms, as well as patients presently showing symptoms.
- Alzheimer's disease virtually anyone is at risk of suffering from Alzheimer's disease if he or she lives long enough. Therefore, the present methods can be administered prophylactically to the general population without the need for any assessment of the risk of the subject patient.
- the present methods are especially useful for individuals who have a known genetic risk of Alzheimer's disease. Such individuals include those having relatives who have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers. Genetic markers of risk toward Alzheimer's disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 refened to as the Hardy and Swedish mutations respectively (see Hardy, supra).
- markers of risk are mutations in the presenilin genes, PS1 and PS2, and ApoE4, family history of AD, hypercholesterolemia or atherosclerosis.
- Individuals presently suffering from Alzheimer's disease can be recognized from characteristic dementia, as well as the presence of risk factors described above.
- a number of diagnostic tests are available for identifying individuals who have AD. These include measurement of CSF tau and A ⁇ 42 levels. Elevated tau and decreased A ⁇ 42 levels signify the presence of AD.
- Individuals suffering from Alzheimer's disease can also be diagnosed by ADRDA criteria as discussed in the Examples section.
- treatment can begin at any age (e.g., 10, 20, 30). Usually, however, it is not necessary to begin treatment until a patient reaches 40, 50, 60 or 70. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody levels over time. If the response falls, a booster dosage is indicated. In the case of potential Down's syndrome patients, treatment can begin antenatally by administering therapeutic agent to the mother or shortly after birth.
- compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of, Alzheimer's disease in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease, including biochemical, histologic and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting dunng development of the disease
- compositions or medicaments are administered to a patient suspected of, or already suffe ⁇ ng from such a disease in an amount sufficient to cure, or at least partially anest, the symptoms of the disease (biochemical, histologic and/or behavioral), including its complications and intermediate pathological phenotypes in development of the disease
- agent reduces or eliminates myocognitive impairment in patients that have not yet developed charactenstic Alzheimer's pathology
- An amount adequate to accomplish therapeutic or prophylactic treatment is defined as a therapeutically- or prophylactically-effective dose
- agents are usually administered in several dosages until a sufficient immune response has been achieved
- the term "immune response” or "immunological response” includes the development of a humoral (antibody mediated) and/or a cellular (mediated by antigen-specific T cells or their secretion products) response directed against an antigen in a recipient subject
- Such a response can be an active response, ; e , induced by administration of immunogen, or a passive response, i e , induced by administration of immunoglobulin or antibody or primed T-cells
- the immune response is monitored and repeated dosages are given if the immune response starts to wane
- Effective doses of the compositions of the present invention, for the treatment of the above descnbed conditions vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic Usually, the patient is a human but non-human mammals including transgenic mammals can also be treated Treatment dosages need to be titrated to optimize safety and efficacy
- the dosage ranges from about 0 0001 to 100 mg/kg, and more usually 0 01 to 5 mg/kg (e , 0 02 mg/kg, 025 mg/kg, 0 5 mg/kg, 0 75 mg/kg, 1 mg kg, 2 mg/kg, etc ), of the host body weight
- dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1- 10 mg/kg, preferably at least 1 mg/kg
- Doses intermediate in the above ranges are also intended to be within the scope of the invention Subjects can be administered such doses daily, on alternative days, weekly or according to any other schedule determined by empirical analysis.
- An exemplary treatment entails administration in multiple dosages over a prolonged period, for example, of at least six months. Additional exemplary treatment regimes entail administration once per every two weeks or once a month or once every 3 to 6 months.
- Exemplary dosage schedules include 1-10 mg kg or 15 mg/kg on consecutive days, 30 mg kg on alternate days or 60 mg/kg weekly.
- two or more monoclonal antibodies with different binding specificities are administered simultaneously, in which case the dosage of each antibody administered falls within the ranges indicated.
- Antibody is usually administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be inegular as indicated by measuring blood levels of antibody to A ⁇ in the patient.
- dosage is adjusted to achieve a plasma antibody concentration of 1-1000 ⁇ g/ml and in some methods 25-300 ⁇ g/ml.
- antibody can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the patient. In general, humanized antibodies show the longest half-life, followed by chimeric antibodies and nonhuman antibodies.
- compositions containing the present antibodies or a cocktail thereof are administered to a patient not already in the disease state to enhance the patient's resistance. Such an amount is defined to be a "prophylactic effective dose.”
- prophylactic effective dose the precise amounts again depend upon the patient's state of health and general immunity, but generally range from 0.1 to 25 mg per dose, especially 0.5 to 2.5 mg per dose.
- a relatively low dosage is administered at relatively infrequent intervals over a long period of time.
- a relatively high dosage e.g., from about 1 to 200 mg of antibody per dose, with dosages of from 5 to 25 mg being more commonly used
- dosages of from 5 to 25 mg are sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease.
- the patent can be administered a prophylactic regime.
- Doses for nucleic acids encoding antibodies range from about 10 ng to 1 g, 100 ng to 100 mg, 1 ⁇ g to 10 mg, or 30-300 ⁇ g DNA per patient
- Doses for infectious viral vectors vary from 10-100, or more, vi ⁇ ons per dose
- Therapeutic agents can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraartal, intracranial, intrapentoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment
- the most typical route of administration of an immunogenic agent is subcutaneous although other routes can be equally effective
- the next most common route is intramuscular injection This type of injection is most typically performed in the arm or leg muscles
- agents are injected directly into a particular tissue where deposits have accumulated, for example intracranial injection
- Intramuscular injection or intravenous infusion are prefened for administration of antibody
- particular therapeutic antibodies are injected directly into the cranium
- antibodies are administered as a sustained release composition or device, such as a MedipadTM device
- Agents of the invention can optionally be administered in combination with other agents that are at least partly effective in treatment of amyloidogenic disease In the case of Alzheimer's and Down's syndrome, in which amyloid deposits occur in the brain, agents of the invention can also be administered in conjunction with other agents that increase passage of the agents of the invention across the blood-brain barner Agents of the invention can also be administered in combination with other agents that enhance access of the therapeutic agent to a target cell or tissue, for example, liposomes and the like Coadmiwel ⁇ ng such agents can decrease the dosage of a therapeutic agent (e g , therapeutic antibody or antibody chain) needed to achieve a desired effect
- a therapeutic agent e g , therapeutic antibody or antibody chain
- compositions compnsing an active therapeutic agent, ; e , and a vanety of other pharmaceutically acceptable components
- the prefe ⁇ ed form depends on the intended mode of administration and therapeutic application
- the compositions can also include, depending on the formulation desired, pharmaceutically- acceptable, non-toxic earners or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration
- the diluent is selected so as not to affect the biological activity of the combination Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution
- the pharmaceutical composition or formulation may also include other earners, adjuvants, or nontoxic, nontherapeutic, nonimmunogemc stabilizers and the like
- compositions can also include large, slowly metabolized macromolecules such as proteins, polysacchandes such as chitosan, polylactic acids, polyglycohc acids and copolymers (such as latex functionahzed sepharose(TM), agarose, cellulose, and the like), polyme ⁇ c amino acids, amino acid copolymers, and hpid aggregates (such as oil droplets or liposomes) Additionally, these earners can function as immunostimulating agents (i e , adjuvants)
- agents of the invention can be administered as injectable dosages of a solution or suspension of the substance in a physiologically acceptable diluent with a pharmaceutical earner that can be a stenle liquid such as water oils, saline, glycerol, or ethanol
- a pharmaceutical earner that can be a stenle liquid such as water oils, saline, glycerol, or ethanol
- auxiliary substances such as wetting or emulsifying agents, surfactants, pH buffenng substances and the like can be present in compositions
- Other components of pharmaceutical compositions are those of petroleum, animal, vegetable, or synthetic ongin, for example, peanut oil, soybean oil, and mineral oil
- glycols such as propylene glycol or polyethylene glycol are prefened liquid earners, particularly for injectable solutions
- Antibodies can be administered in the form of a depot injection or implant preparation, which can be formulated in such a manner as to permit a sustained release of the active ingredient
- An exemplary composition compnses monoclon
- compositions are prepared as injectables, either as liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid vehicles pnor to injection can also be prepared
- the preparation also can be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycohde, or copolymer for enhanced adjuvant effect, as discussed above (see Langer, Science 249 1527 (1990) and Hanes, Advanced Drug Delivery Reviews 28 97 (1997))
- the agents of this invention can be administered in the form of a depot injection or implant preparation, which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient
- binders and earners include, for example, polyalkylene glycols or tnglycendes, such suppositories can be formed from mixtures containing the active ingredient in the range of 0 5% to 10%, preferably l%-2%
- Oral formulations include excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccha ⁇ ne, cellulose, and magnesium carbonate
- compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably
- Topical application can result in transdermal or intradermal delivery
- Topical administration can be facilitated by co-administration of the agent with cholera toxin or detoxified de ⁇ vatives or subumts thereof or other similar bacte ⁇ al toxins (See
- Co-administration can be achieved by using the components as a mixture or as linked molecules obtained by chemical crosshnking or expression as a fusion protein
- transdermal delivery can be achieved using a skin path or using transferosomes (Paul et al , Eur J Immunol 25 3521 (1995), Cevc et al ,
- the invention provides methods of monitonng treatment in a patient suffering from or susceptible to Alzheimer's, i e , for monitonng a course of treatment being administered to a patient
- the methods can be used to monitor both therapeutic treatment on symptomatic patients and prophylactic treatment on asymptomatic patients
- the methods are useful for monitonng passive immunization (e g , measunng level of administered antibody)
- Some methods entail determining a baseline value, for example, of an antibody level or profile in a patient, before administenng a dosage of agent, and comparing this with a value for the profile or level after treatment
- a significant increase i e , greater than the typical margin of expenmental enor m repeat measurements of the same sample, expressed as one standard deviation from the mean of such measurements
- a positive treatment outcome i e , that administration of the agent has achieved a desired response
- a negative treatment outcome is indicated
- a control value (i e , a mean and standard deviation) of level or profile is determined for a control population Typically the individuals in the control population have not received pnor treatment Measured values of the level or profile in a patient after administenng a therapeutic agent are then compared with the control value A significant increase relative to the control value (e g , greater than one standard deviation from the mean) signals a positive or sufficient treatment outcome A lack of significant increase or a decrease signals a negative or insufficient treatment outcome Administration of agent is generally continued while the level is increasing relative to the control value As before, attainment of a plateau relative to control values is an indicator that the administration of treatment can be discontinued or reduced in dosage and/or frequency
- a control value of the level or profile (e , a mean and standard deviation) is determined from a control population of individuals who have undergone treatment with a therapeutic agent and whose levels or profiles have plateaued in response to treatment Measured values of levels or profiles in a patient are compared with the control value If the measured level in a patient is not significantly different (e g , more than one standard deviation) from the control value, treatment can be discontinued If the level in a patient is significantly below the control value, continued administration of agent is wa ⁇ anted If the level in the patient persists below the control value, then a change in treatment may be indicated
- a patient who is not presently receiving treatment but has undergone a previous course of treatment is monitored for antibody levels or profiles to determine whether a resumption of treatment is required
- the measured level or profile in the patient can be compared with a value previously achieved in the patient after a previous course of treatment
- a sigmficant decrease relative to the previous measurement is an indication that treatment can be resumed
- the value measured in a patient can be compared with a control value (mean plus standard deviation) determined in a population of patients after undergoing a course of treatment
- the measured value in a patient can be compared with a control value in populations of prophylactically treated patients who remain free of symptoms of disease, or populations of therapeutically treated patients who show amelioration of disease characte ⁇ stics
- a significant decrease relative to the control level i e , more than a standard deviation
- the tissue sample for analysis is typically blood, plasma, serum, mucous fluid or cerebrospmal fluid from the patient
- the sample is analyzed, for example, for levels or profiles of antibodies to A ⁇ peptide, e g , levels or profiles of humanized antibodies
- ELISA methods of detecting antibodies specific to A ⁇ are descnbed in the Examples section
- the level or profile of an administered antibody is determined using a cleanng assay, for example, in an in vitro phagocytosis assay, as descnbed herein
- a tissue sample from a patient being tested is contacted with amyloid deposits (e g , from a PDAPP mouse) and phagocytic cells beanng Fc receptors Subsequent cleanng of the amyloid deposit is then monitored
- amyloid deposits e g , from a PDAPP mouse
- the antibody profile following passive immunization typically shows an immediate peak in antibody concentration followed by an exponential decay Without a further dosage, the decay approaches pretreatment levels within a pe ⁇ od of days to months depending on the half-life of the antibody administered
- a baseline measurement of antibody to A ⁇ m the patient is made before administration, a second measurement is made soon thereafter to determine the peak antibody level, and one or more further measurements are made at intervals to monitor decay of antibody levels
- a predetermined percentage of the peak less baseline e g , 50%, 25% or 10%
- administration of a further dosage of antibody is administered
- peak or subsequent measured levels less background are compared with reference levels previously determined to constitute a beneficial prophylactic or therapeutic treatment regime in other patients If the measured antibody level is significantly less than a reference level (eg , less than the mean minus one standard deviation of the reference value m population of patients benefiting from treatment) administration of an additional dosage of antibody is indicated
- Additional methods include monitoring, over the course of treatment, any art-recognized physiologic symptom (e , physical or mental symptom) routinely relied on by researchers or physicians to diagnose or monitor amyloidogenic diseases (e g , Alzheimer's disease)
- physiologic symptom e , physical or mental symptom
- amyloidogenic diseases e g , Alzheimer's disease
- cognitive impairment can be monitored by determining a patient's score on the Mini-Mental State Exam in accordance with convention throughout the course of treatment
- kits for performing the monitonng methods descnbed above typically contain an agent that specifically binds to antibodies to A ⁇
- the kit can also include a label For detection of antibodies to A ⁇ , the label is typically in the form of labeled anti-idiotypic antibodies
- the agent can be supplied prebound to a solid phase, such as to the wells of a microtiter dish Kits also typically contain labeling providing directions for use of the kit
- the labeling may also include a chart or other conespondence regime conelating levels of measured label with levels of antibodies to A ⁇
- the term labeling refers to any written or recorded matenal that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use
- the term labeling encompasses advertising leaflets and brochures, packaging matenals, instructions, audio or videocassettes, computer discs, as well as w ⁇ ting imprinted directly on kits
- the invention also provides diagnostic kits, for example, research, detection and/or diagnostic kits (e ,
- the invention provides methods of in vivo imaging amyloid deposits in a patient. Such methods are useful to diagnose or confirm diagnosis of Alzheimer's disease, or susceptibility thereto. For example, the methods can be used on a patient presenting with symptoms of dementia. If the patient has abnormal amyloid deposits, then the patient is likely suffering from Alzheimer's disease. The methods can also be used on asymptomatic patients. Presence of abnormal deposits of amyloid indicates susceptibility to future symptomatic disease. The methods are also useful for monitoring disease progression and/or response to treatment in patients who have been previously diagnosed with Alzheimer's disease.
- the methods work by administering a reagent, such as antibody that binds to A ⁇ , to the patient and then detecting the agent after it has bound.
- a reagent such as antibody that binds to A ⁇
- Prefened antibodies bind to A ⁇ deposits in a patient without binding to full length APP polypeptide.
- Antibodies binding to an epitope of A ⁇ within amino acids 1-10 are particularly prefe ⁇ ed.
- the antibody binds to an epitope within amino acids 7-10 of A ⁇ .
- Such antibodies typically bind without inducing a substantial clearing response.
- the antibody binds to an epitope within amino acids 1-7 of A ⁇ .
- Such antibodies typically bind and induce a clearing response to A ⁇ .
- the clearing response can be avoided by using antibody fragments lacking a full-length constant region, such as Fabs.
- the same antibody can serve as both a treatment and diagnostic reagent.
- antibodies binding to epitopes C-terminal to residue 10 of A ⁇ do not show as strong a signal as antibodies binding to epitopes within residues 1-10, presumably because the C-terminal epitopes are inaccessible in amyloid deposits. Accordingly, such antibodies are less prefened.
- Diagnostic reagents can be administered by intravenous injection into the body of the patient, or directly into the brain by intracranial injection or by drilling a hole through the skull. The dosage of reagent should be within the same ranges as for treatment methods.
- the reagent is labeled, although in some methods, the primary reagent with affinity for A ⁇ is unlabelled and a secondary labeling agent is used to bind to the primary reagent.
- a secondary labeling agent is used to bind to the primary reagent.
- the choice of label depends on the means of detection. For example, a fluorescent label is suitable for optical detection. Use of paramagnetic labels is suitable for tomographic detection without surgical intervention. Radioactive labels can also be detected using PET or SPECT.
- Diagnosis is performed by comparing the number, size, and/or intensity of labeled loci, to co ⁇ esponding baseline values.
- the base line values can represent the mean levels in a population of undiseased individuals. Baseline values can also represent previous levels determined in the same patient. For example, baseline values can be determined in a patient before beginning treatment, and measured values thereafter compared with the baseline values. A decrease in values relative to baseline signals a positive response to treatment.
- an antibody or immunoglobulin sequence comprising a VL and/or VH sequence as set forth in any one of SEQ ID NOs: 1-12 or 29-38 can comprise either the full sequence or can comprise the mature sequence (i.e., mature peptide without the signal or leader peptide).
- Table 3 Mouse 12B4 VH amino acid sequence mdrltssflllivpayvlsqVTLKESGPGILQPSQTLSLTCSFSGFS StngmgvsWIR QPSGKGLE LAhiywdedkrynpslksRLTISKDTSNNQVFLKITNVDTADTATYYCAR rriiydvedyfdyWGQGTTLTVSS (SEQ ID NO: 4)
- the light chain variable VL region of 12B4 was cloned in an analogous manner as the VH region.
- the nucleotide sequence (SEQ ID NO:l) and deduced amino acid sequence (SEQ ED NO:2) derived from two independent cDNA clones encoding the presumed 12B4 VL domain, are set forth in Table 4 and Table 5, respectively.
- the 12B4 VL and VH sequences meet the c ⁇ te ⁇ a for functional V regions in so far as they contain a contiguous ORF from the initiator methionine to the C-region, and share conserved residues charactenstic of immunoglobulin V region genes From N-terminal to C-temunal, both light and heavy chains comp ⁇ se the domains FRl , CDRl , FR2, CDR2, FR3, CDR3 and FR4
- the assignment of amino acids to each domain is in accordance with the numbenng convention ot Kabat et al , supra
- Figure 5 demonstrates that chimeric 12B4 was found to bind to A ⁇ with high avidity, similar to that demonstrated by chimeric and humanized 3D6 ( Figure 5).
- the cloning, characterization and humanization of 3D6 is described in U.S. Patent Application Serial No. 10/010,942, the entire content of which is incorporated herein by this reference.
- an ELISA based competitive inhibition assay revealed that the chimeric 12B4 and the murine 12B4 antibody competed equally with biotinylated murine and chimeric 3D6, as well as 10D5 (a murine monoclonal antibody of the IgG ⁇ l isotype which recognizes the same epitope as 12B4), in binding to A ⁇ .
- Figure 6 demonstrates that chimeric 12B4 (dashed line, open triangles) competes with equal potency with its non biotinylated murine counterpart (solid line, closed triangles) for binding of biotinylated murine 12B4 to A ⁇ 1-42 peptide.
- Example III Efficacy of mAb 12B4 on various neuropathological endpoints in PDAPP mice
- PDAPP mice were passively immunized with either mAb 12B4 (recognizing A ⁇ 3-7) or mAb 3D6 (recognizing A ⁇ 1-5), both of the IgG ⁇ 2a isotype. 12B4 was tested at 10 mg/kg. 3D6 was administered at three different doses, 10 mg/kg, 1 mg/kg and 10 mg/kg once a month (1 x 4). An unrelated IgG ⁇ 2a antibody (TY 11/15) and PBS injections served as controls. Active immunization with A ⁇ peptide served as a comparison. Between 20 and 35 animals were analyzed in each group.
- the neuropathological endpoints assayed include amyloid burden and neuritic burden.
- Amyloid burden includes amyloid burden and neuritic burden.
- Neuritic burden following passive immunization with 12B4 versus 3D6 was thus determined in PDAPP mice by immunostaining of brain sections with anti-APP antibody 8E5 followed by quantitative image analysis. Neuritic dystrophy is indicated by the appearance of dystrophic neurites (e.g., neurites with a globular appearance) located in the immediate vicinity of amyloid plaques. The results of this analysis are shown in Table 7. These data indicate that treatment with 12B4 most significantly reduced neuritic burden. By contrast, 3D6 did not significantly reduce neuritic burden.
- PDAPP mouse model of Alzheimer's disease provides valuable information to be used by the skilled artisan in designing appropriate human therapeutic immunization protocols. For example, reduction of neuritic burden may be accomplished in human subjects using a humanized version of 12B4 of the IgGl subtype (i.e., the human equivalent of the IgG ⁇ 2A subtype in mice) which binds to an epitope within residues 3-7 ofA ⁇ .
- a humanized version of 12B4 of the IgGl subtype i.e., the human equivalent of the IgG ⁇ 2A subtype in mice
- Example IV Ex vivo Screening Assay for Activity of Antibodies against Amyloid Deposits
- an ex vivo assay was utilized in which primary microghal cells were cultured with unfixed cryostat sections of either PDAPP mouse or human AD brains. Microghal cells were obtained from the cerebral cortices of neonate DBA/2N mice (1-3 days). The cortices were mechanically dissociated in HBSS " (Hanks' Balanced Salt Solution, Sigma) with 50 ⁇ g/ml DNase E (Sigma). The dissociated cells were filtered with a 100 ⁇ m cell strainer (Falcon), and centrifuged at 1000 rpm for 5 minutes.
- the pellet was resuspended in growth medium (high glucose DMEM, 10%FBS, 25ng/ml recombinant murine GM-CSF (rmGM-CSF), and the cells were plated at a density of 2 brains per T-75 plastic culture flask. After 7-9 days, the flasks were rotated on an orbital shaker at 200 rpm for 2h at 37°C. The cell suspension was centrifuged at lOOOrpm and resuspended in the assay medium.
- growth medium high glucose DMEM, 10%FBS, 25ng/ml recombinant murine GM-CSF (rmGM-CSF)
- cryostat sections of PDAPP mouse or human AD brains were thaw mounted onto poly-lysine coated round glass coverslips and placed in wells of 24-well tissue culture plates.
- the coverslips were washed twice with assay medium consisting of H-SFM (Hybridoma-serum free medium, Gibco BRL) with 1% FBS, glutamine, penicillin/streptomycin, and 5ng/ml rmGM-CSF (R&D).
- Control or anti-A ⁇ antibodies (12B4) were added at a 2x concentration (5 ⁇ g/ml final) for 1 hour
- the microghal cells were then seeded at a density of 0 8x 10 6 cells/ml assay medium
- the cultures were maintained in a humidified incubator (37°C, 5%C ⁇ 2 ) for 24hr or more
- the cultures were fixed with 4% paraformaldehyde and permeabihzed with 0 1% Tnton-XlOO
- the sections were stained with biotinylated 3D6 followed by a streptavidin / Cy3 conjugate (Jackson
- a first pass homology model of 12B4 variable region based on the antibodies noted above was constructed using the Look & SegMod Modules GeneMine (v3.5) software package. This software was purchased under a pe ⁇ etual license from Molecular Applications Group (Palo Alto, CA). This software package, authored by Drs. Michael Levitt and Chris Lee, facilitates the process of molecular modeling by automating the steps involved in structural modeling a primary sequence on a template of known structure based on sequence homology. Working on a Silicon Graphics ERES workstation under a UNIX environment, the modeled structure is automatically refined by a series of energy minimization steps to relieve unfavorable atomic contacts and optimize electrostatic and van der Walls interactions. A further refined model was built using the modeling capability of Quanta®.
- Suitable human acceptor antibody sequences were identified by computer comparisons of the amino acid sequences of the mouse variable regions with the sequences of known human antibodies. The comparison was performed separately for the 12B4 heavy and light chains.
- variable domains from human antibodies whose framework sequences exhibited a high degree of sequence identity with the murine VL and VH framework regions were identified by query of the Kabat Database using NCBI BLAST (publicly accessible through the National Institutes of Health NCBI internet server) with the respective murine framework sequences.
- acceptor sequences Two candidate sequences were chosen as acceptor sequences based on the following criteria: (1) homology with the subject sequence; (2) sharing canonical CDR structures with the donor sequence; and (3) not containing any rare amino acid residues in the framework regions.
- the selected acceptor sequence for VL is Kabat ED Number (KABID) 005036 (Genbank Accession No. X67904), and for VH is KABID 000333 (Genbank Accession No. X54437).
- First versions of humanized 3D6 antibody utilize these selected acceptor antibody sequences.
- the humanized antibodies of the invention comp ⁇ se vanable framework regions substantially from a human immunoglobulin (acceptor immunoglobulin) and complementa ⁇ ty determining regions substantially from a mouse immunoglobulin (donor immunoglobulin) termed 12B4 Having identified the complementa ⁇ ty determining regions of 12B4 and approp ⁇ ate human acceptor immunoglobulins, the next step was to determine which, if any, residues from these components to substitute to optimize the properties of the resulting humanized antibody
- Figure 1 The choice of the acceptor framework (Kabid 005036) is from the same human subgroup as that which co ⁇ esponds to the mu ⁇ ne V region, has no unusual framework residues, and the CDRs belong to the same Chothia canonical structure groups A single back mutation (I2V) is dictated as this residue falls into the canonical classification Version 1 of the reshaped VL is fully germline
- the amino acid alignment of the reshaped heavy chain V region is shown in Figure 2
- the choice for the acceptor framework is from the same human subgroup as that which co ⁇ esponds to the munne V region, has no unusual framework residues, and the CDRs belong to the same Chothia canonical groups Structural modeling of the munne VH chain, m conjunction with the amino acid alignment of Kabid 000333 to the munne sequence dictates 9 back-mutations in version 1 (vl) of the reshaped heavy chain L2V, V24F, G27F, I29L, I48L, G49A, V67L, V71K, & F78V (Kabat numbenng) The back mutations are highlighted by astensks in the amino-acid alignment shown in Figure 2
- Version 2 was designed to retain the lowest number of non-CDR murine residues.
- the L2 V backmutation introduces a non-germline change (when using VH4- 61 as the germline reference), and this backmutation is eliminated in version 2 of the heavy chain to restore it to germ line.
- the remaining 4 vernier class back mutations are also restored in version 2 of the heavy chain (I48L, G49A, V67L, F78V). Version 2 thus contain a total of 5 non-CDR murine residues (1 in VL, and 4 in VH).
- Version 3 was designed to restore 2 of the 5 vernier residues (I48L, & F78V), which the model indicates may be the more important vernier residues. Hence version 3 contains a total of 7 non CDR murine residues.
- Tables 10 and 11 set forth Kabat numbering keys for the various light and heavy chains, respectively.
- V V I I canonical - backmutate in vl , v2 and v3
- the humanized antibodies preferably exhibit a specific binding affinity for A ⁇ of at least 10 7 , 10 8 , 10 9 or 10 10 M '
- the upper limit of binding affinity of the humanized antibodies for A ⁇ is within a factor of three, four or five of that of 12B4 (i e , ⁇ 10 9 M ')
- the lower limit of binding affinity is also withm a factor of three, four or five of that of 12B4
- Figure 9a is a schematic representation of the strategy for PCR mediated assembly of humanized VL vl
- Figure 9b is a schematic representation of the strategy for PCR mediated assembly of humanized VH vl
- Table 11 sets forth primers used for the PCR- mediated assembly of 12B4vl Table 11 : Synthetic oligonucleotides used in PCR mediated assembly of humanized 12B4 V regions, vl
- VHvl A+ VHvlB and VHvlC+VHvlD synthetic fragments were annealed as pairs, in separate reaction tubes using standard procedures.
- the C+D annealing reaction was assembled using PCR primers C+Dfor and C+Dback under identical conditions.
- the PCR-assembled 5' A+B half, and 3' C+D half, were gel purified for a final PCR-mediated assembly.
- Full V region assembly was effected by mixing the A+B assembled 5' half with the C+D 3' half of the V-region, annealing, and extending by PCR using VHvl A+B for primer, and VHvl C+D back primer.
- the full length VH and VL regions assembled in this manner were gel purified, and cloned into pCRScript for DNA sequence verification.
- a second version of humanized 12B4 was created having each of the substitutions indicated for version 1, except for the L- ⁇ V substitution at residue 2, the I-> L substitution at residue 48, the G-> A substitution at residue 49, the V- L substitution at residue 67 and the F-> V substitution at residue 78.
- the nucleotide sequences of humanized 3D6 version 2 light and heavy chains are set forth as SEQ ID NOs: 9 and 11, respectively.
- the nucleotide sequences of humanized 3D6 version 2 light and heavy chains are set forth as SEQ ID NOs: 1 and 9, respectively.
- the amino acid sequences of humanized 3D6 version 2 light and heavy chains are set forth as SEQ ID NOs: 2 and 10, respectively.
- a third version of humanized 12B4 was created having each of the substitutions indicated for version 1 , except for the L- ⁇ V substitution at residue 2, the G- A substitution at residue 49 and the V-> L substitution at residue 67.
- the nucleotide sequences of humanized 3D6 version 2 light and heavy chains are set forth as SEQ ID NOs: 1 and 9, respectively.
- the nucleotide sequences of humanized 3D6 version 3 light and heavy chains are set forth as SEQ ID NOs: 1 and 11, respectively.
- the amino acid sequences of humanized 3D6 version 3 light and heavy chains are set forth as SEQ ID NOs: 2 and 12, respectively.
- Example VI Prevention and Treatment of Human Subjects
- a single-dose phase I trial is performed to determine safety in humans.
- a therapeutic agent is administered in increasing dosages to different patients starting from about 0.01 the level of presumed efficacy, and increasing by a factor of three until a level of about 10 times the effective mouse dosage is reached.
- a phase II trial is performed to determine therapeutic efficacy.
- Patients with early to mid Alzheimer's Disease defined using Alzheimer's disease and Related Disorders Association (ADRDA) criteria for probable AD are selected. Suitable patients score in the 12-26 range on the Mini-Mental State Exam (MMSE). Other selection criteria are that patients are likely to survive the duration of the study and lack complicating issues such as use of concomitant medications that may interfere.
- Baseline evaluations of patient function are made using classic psychometric measures, such as the MMSE, and the ADAS, which is a comprehensive scale for evaluating patients with Alzheimer's Disease status and function. These psychometric scales provide a measure of progression of the Alzheimer's condition. Suitable qualitative life scales can also be used to monitor treatment. Disease progression can also be monitored by MRI. Blood profiles of patients can also be monitored including assays of immunogen-specific antibodies and T-cells responses. Following baseline measurements, patients begin receiving treatment.
- a second phase II trial is performed to evaluate conversion of patients from non-Alzheimer's Disease early memory loss, sometimes refe ⁇ ed to as age- associated memory impairment (AAMI) or mild cognitive impairment (MCI), to probable Alzheimer's disease as defined as by ADRDA criteria.
- AAMI age- associated memory impairment
- MCI mild cognitive impairment
- Patients with high risk for conversion to Alzheimer's Disease are selected from a non-clinical population by screening reference populations for early signs of memory loss or other difficulties associated with pre-Alzheimer's symptomatology, a family history of Alzheimer's
- the invention provides for a number of uses.
- the invention provides for the use of any of the antibodies to A ⁇ described above in the treatment, prophylaxis or diagnosis of amyloidogenic disease, or in the manufacture of a medicament or diagnostic composition for use in the
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN038058162A CN1703426B (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
MXPA04008740A MXPA04008740A (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide. |
IL16362603A IL163626A0 (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
EP03711559A EP1554311B1 (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
JP2003575912A JP2006503549A (en) | 2002-03-12 | 2003-03-12 | Humanized antibody that recognizes β-amyloid peptide |
NZ535769A NZ535769A (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
ES03711559T ES2389541T3 (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta-amyloid peptide |
EA200401170A EA010902B1 (en) | 2002-03-12 | 2003-03-12 | Humanized immunoglobulin, that recognizes beta amyloid peptide, pharmaceutical composition and method for producing thereof |
CA2478049A CA2478049C (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
AU2003214152A AU2003214152B2 (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
BRPI0308143-5A BR0308143A (en) | 2002-03-12 | 2003-03-12 | light chain, heavy chain, immunoglobulin, humanized antibody. pharmaceutical and therapeutic composition, isolated polypeptide and peptide, polypeptide variant, isolated nucleic acid molecule, vector, host cell, transgenic animal, use of the variable region sequence presented as sequence id: 2 or sequence id. 4 and methods of preventing or treating an amyloidogenic disease associated with amyloid deposition of fir trees in a patient's brain and alzheimer's disease, of producing an antibody or fragment thereof, of identifying residues sensitive to substitution in a variable frame region of immunoglobulin , imaging of amyloid deposits in a patient's brain and reducing plaque, neuter and beta amyloid peptide (fir) load and neuritically dystrophy |
IL163626A IL163626A (en) | 2002-03-12 | 2004-08-19 | Humanized antibodies that recognize beta amyloid peptide |
NO20043992A NO20043992L (en) | 2002-03-12 | 2004-09-23 | Humanized antibodies that recognize beta amyloid peptide |
IS7499A IS7499A (en) | 2002-03-12 | 2004-10-11 | Human antibodies against beta-amyloid peptides |
HR20040950A HRP20040950A2 (en) | 2002-03-12 | 2004-10-12 | Humanized antibodies that recognize beta amyloid peptide |
HK06105249.2A HK1085222A1 (en) | 2002-03-12 | 2006-05-03 | Humanized antibodies that recognize beta amyloid peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36375102P | 2002-03-12 | 2002-03-12 | |
US60/363751 | 2002-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003077858A2 true WO2003077858A2 (en) | 2003-09-25 |
WO2003077858A3 WO2003077858A3 (en) | 2005-05-19 |
Family
ID=28041806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/007715 WO2003077858A2 (en) | 2002-03-12 | 2003-03-12 | Humanized antibodies that recognize beta amyloid peptide |
Country Status (30)
Country | Link |
---|---|
US (2) | US7256273B2 (en) |
EP (1) | EP1554311B1 (en) |
JP (1) | JP2006503549A (en) |
KR (2) | KR20110027846A (en) |
CN (1) | CN1703426B (en) |
AR (1) | AR038953A1 (en) |
AU (1) | AU2003214152B2 (en) |
BR (1) | BR0308143A (en) |
CA (1) | CA2478049C (en) |
CO (1) | CO5611164A2 (en) |
EA (1) | EA010902B1 (en) |
EC (1) | ECSP045314A (en) |
ES (1) | ES2389541T3 (en) |
GE (1) | GEP20084474B (en) |
HK (1) | HK1085222A1 (en) |
HR (1) | HRP20040950A2 (en) |
IL (2) | IL163626A0 (en) |
IS (1) | IS7499A (en) |
MX (1) | MXPA04008740A (en) |
MY (1) | MY139983A (en) |
NO (1) | NO20043992L (en) |
NZ (1) | NZ535769A (en) |
PE (1) | PE20040207A1 (en) |
PL (1) | PL215258B1 (en) |
SG (1) | SG180018A1 (en) |
TW (1) | TWI328116B (en) |
UA (1) | UA89469C2 (en) |
UY (1) | UY27721A1 (en) |
WO (1) | WO2003077858A2 (en) |
ZA (1) | ZA200406616B (en) |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026408A3 (en) * | 2004-08-27 | 2006-05-04 | Wyeth Res Ireland Ltd | Production of anti-amyloid beta antibodies |
WO2006066171A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
WO2006066089A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006036291A3 (en) * | 2004-07-30 | 2006-07-20 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006066049A3 (en) * | 2004-12-15 | 2006-10-05 | Neuralab Ltd | Humanized antibodies that recognize beta amyloid peptide |
WO2006118959A2 (en) * | 2005-04-29 | 2006-11-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
JP2007525160A (en) * | 2003-03-12 | 2007-09-06 | ニユーララブ・リミテツド | Humanized antibody that recognizes β-amyloid peptide |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
JP2007536895A (en) * | 2003-05-30 | 2007-12-20 | ニユーララブ・リミテツド | Humanized antibody that recognizes beta amyloid peptide |
JP2008515430A (en) * | 2004-10-05 | 2008-05-15 | エラン ファーマ インターナショナル リミテッド | Methods and compositions for improving recombinant protein production |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
WO2008084402A3 (en) * | 2007-01-11 | 2009-04-09 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
EP2182983A1 (en) * | 2007-07-27 | 2010-05-12 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US7820799B2 (en) | 2005-06-17 | 2010-10-26 | Janssen Alzheimer Immunotherapy | Methods of purifying Fc region containing proteins |
US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
US8034339B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
EP2392353A1 (en) | 2005-01-28 | 2011-12-07 | Janssen Alzheimer Immunotherapy | Anti A beta antibody formulation |
WO2012000094A1 (en) * | 2010-06-30 | 2012-01-05 | Mount Sinai Hospital | REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α |
JP2012034697A (en) * | 2011-09-16 | 2012-02-23 | Janssen Alzheimer Immunotherapy | HUMANIZED ANTIBODY RECOGNIZING β-AMYLOID PEPTIDE |
US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9090680B2 (en) | 2008-02-08 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to abeta oligomers and uses thereof |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
EP2952524A1 (en) | 2007-10-17 | 2015-12-09 | Janssen Sciences Ireland UC | Immunotherapy regimes dependent on apoe status |
US9211330B2 (en) | 2010-03-03 | 2015-12-15 | Ablynx N.V. | A-beta binding polypeptides |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016081643A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
WO2016094566A2 (en) | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9670272B2 (en) | 2007-01-05 | 2017-06-06 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US10336820B2 (en) | 2008-02-20 | 2019-07-02 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
EP3594240A1 (en) | 2013-05-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
WO2020072357A1 (en) | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
WO2020132230A2 (en) | 2018-12-20 | 2020-06-25 | Genentech, Inc. | Modified antibody fcs and methods of use |
WO2020156222A1 (en) * | 2019-02-01 | 2020-08-06 | 长春金赛药业有限责任公司 | HUMANIZED ANTI-Aβ MONOCLONAL ANTIBODY AND APPLICATION THEREOF |
US10842871B2 (en) | 2014-12-02 | 2020-11-24 | Biogen International Neuroscience Gmbh | Methods for treating Alzheimer's disease |
RU2783528C1 (en) * | 2019-02-01 | 2022-11-14 | Чанчунь Джинсайенс Фармасьютикал Ко., Лтд. | HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE |
US11530257B2 (en) | 2017-06-29 | 2022-12-20 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies for treatment of amyloid deposition diseases |
US11655289B2 (en) | 2017-08-22 | 2023-05-23 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
PE20020574A1 (en) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
CA2513722A1 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
US20060024667A1 (en) * | 2004-07-29 | 2006-02-02 | Karen Manucharyan | Compositions and methods for Alzheimer's disease |
AU2006203889A1 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | CRIPTO binding molecules |
WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
GT200600033A (en) * | 2005-01-28 | 2006-10-25 | POLYPEPTIDE STABILIZED LIQUID FORMULATIONS | |
TWI382990B (en) * | 2005-12-12 | 2013-01-21 | Hoffmann La Roche | Antibody glycosylation in the variable region |
JP5419131B2 (en) | 2005-12-12 | 2014-02-19 | エーシー イミューン ソシエテ アノニム | Β1-42 specific monoclonal antibodies with therapeutic properties |
TWI551607B (en) | 2006-07-14 | 2016-10-01 | Ac免疫公司 | Humanized antibody |
WO2008070284A2 (en) | 2006-10-16 | 2008-06-12 | Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute | Amyloid beta peptides and methods of uses thereof |
PT2426143T (en) * | 2007-01-05 | 2017-09-22 | Univ Zuerich | Method of providing disease-specific binding molecules and targets |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
BRPI0810118A8 (en) * | 2007-04-18 | 2015-09-29 | Janssen Alzheimer Immunotherap | METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
CA2707309A1 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
SG186689A1 (en) * | 2007-12-28 | 2013-01-30 | Univ Tennessee Res Foundation | Treatment and prophylaxis of amyloidosis |
CA2724886C (en) | 2008-05-23 | 2017-11-14 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
SI2949666T1 (en) | 2008-12-19 | 2019-03-29 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
US8614297B2 (en) * | 2008-12-22 | 2013-12-24 | Hoffmann-La Roche Inc. | Anti-idiotype antibody against an antibody against the amyloid β peptide |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
CA2791648A1 (en) | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
RU2607368C2 (en) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Safe and functional humanized antibodies |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
CA2839563C (en) | 2011-06-23 | 2019-10-29 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
JP2014001232A (en) * | 2013-09-02 | 2014-01-09 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic disease |
WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
KR102438295B1 (en) | 2014-09-19 | 2022-08-31 | 시와 코퍼레이션 | Anti-age antibodies for treating inflammation and auto-immune disorders |
CN107208076A (en) | 2014-10-17 | 2017-09-26 | 科达制药 | Butyrylcholine esterase amphoteric ion polymer conjugate |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
KR20180020169A (en) | 2015-06-24 | 2018-02-27 | 에프. 호프만-라 로슈 아게 | Anti-transferrin receptor antibody with adjusted affinity |
CN114057885A (en) | 2015-10-02 | 2022-02-18 | 豪夫迈·罗氏有限公司 | Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CN108350052A (en) * | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | Epitope in amyloid beta intermediate region and its conformation antibodies selective |
US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
CA3004498A1 (en) * | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
JP2016047839A (en) * | 2015-11-24 | 2016-04-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Treatment of amyloidogenic disease |
EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
PT3337829T (en) | 2016-02-19 | 2020-02-10 | Siwa Corp | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
JP2020516648A (en) | 2017-04-13 | 2020-06-11 | シワ コーポレーション | Humanized monoclonal advanced glycation end product antibody |
US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
CN113692413A (en) | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | Efflux pump-cancer antigen multispecific antibodies and compositions, reagents, kits and methods related thereto |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN116529267A (en) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | ABCG2 efflux pump-cancer antigen multispecific antibodies and related compositions, reagents, kits and methods |
KR20230039734A (en) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | anti-Aβ antibody |
TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (352)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096318A (en) | 1973-05-07 | 2000-08-01 | The Ohio State University | Antigenically modified HCG polypeptides |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5158769A (en) | 1984-03-07 | 1992-10-27 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4713366A (en) | 1985-12-04 | 1987-12-15 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
US5096706A (en) | 1986-03-25 | 1992-03-17 | National Research Development Corporation | Antigen-based treatment for adiposity |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5278049A (en) | 1986-06-03 | 1994-01-11 | Incyte Pharmaceuticals, Inc. | Recombinant molecule encoding human protease nexin |
US5231170A (en) | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5223482A (en) | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
US5220013A (en) | 1986-11-17 | 1993-06-15 | Scios Nova Inc. | DNA sequence useful for the detection of Alzheimer's disease |
US5187153A (en) | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
US4879213A (en) | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
US4912206A (en) | 1987-02-26 | 1990-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | CDNA clone encoding brain amyloid of alzheimer's disease |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5245015A (en) | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
US5583112A (en) | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912506A (en) * | 1987-06-10 | 1990-03-27 | Brother Kogyo Kabushiki Kaisha | Image recording apparatus having exposure unit |
US5849298A (en) | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5571500A (en) | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5641474A (en) | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
JP2512796B2 (en) | 1987-06-24 | 1996-07-03 | オートイミュン・インコーポレイテッド | Treatment of autoimmune disease by oral administration of self-antigen |
US5645820A (en) | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5571499A (en) | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5869054A (en) | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
WO1989003687A1 (en) | 1987-10-23 | 1989-05-05 | Genetics Institute, Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
WO1989006689A1 (en) | 1988-01-13 | 1989-07-27 | The Mclean Hospital Corporation | Genetic constructs containing the alzheimer brain amyloid gene |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
JPH04501719A (en) | 1988-11-10 | 1992-03-26 | インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド | polypeptide |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
WO1990012870A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
WO1990012871A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
ES2144398T3 (en) | 1989-12-20 | 2000-06-16 | Autoimmune Inc | IMPROVED TREATMENT OF AUTOIMMUNE DISEASES THROUGH THE ADMINISTRATION IN SELF-ANTIGEN SPRAY. |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
JPH05508621A (en) | 1990-03-02 | 1993-12-02 | オートイミューン インク | Down control of autoimmune diseases by oral administration of autoantigens |
CA2079880A1 (en) | 1990-04-24 | 1991-10-25 | William E. Van Nostrand | Purification, detection and methods of use of protease nexin-2 |
GB9009548D0 (en) | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
ATE153534T1 (en) | 1990-04-27 | 1997-06-15 | John Mcmichael | METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
ES2217250T3 (en) | 1990-06-15 | 2004-11-01 | Scios Inc. | TRANSGENIC, NON-HUMAN MAMMER THAT SHOWS THE AMILOID TRAINING PATHOLOGY OF ALZHEIMER'S DISEASE. |
EP0537247A4 (en) | 1990-06-19 | 1993-09-08 | Immuvax | Nonpathogenic variant virus |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
US6506728B2 (en) | 1990-09-25 | 2003-01-14 | Genentech, Inc. | Methods using a novel neurotrophic factor, NT-4 |
JPH06502071A (en) | 1990-09-28 | 1994-03-10 | ジ・アップジョン・カンパニー | Transgenic animals carrying Alzheimer's amyloid precursor gene |
ATE175118T1 (en) | 1990-10-05 | 1999-01-15 | Medarex Inc | TARGETED IMMUNOSTIMULATION WITH BISPECIFIC SUBSTANCES |
KR0140841B1 (en) | 1990-10-15 | 1998-06-01 | 조앤 월리스 | Treatment of autoimmune diseases by oral administration of autoantigens |
GB9023352D0 (en) | 1990-10-26 | 1990-12-05 | Lynxvale Ltd | Vaccinia vectors,vaccinia genes and expression products thereof |
ATE286971T1 (en) | 1991-01-21 | 2005-01-15 | Elan Pharm Inc | TEST AND MODEL FOR ALZHEIMERS DISEASE |
CA2081660C (en) | 1991-03-01 | 2001-05-01 | Raymond Dufour | Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals and vaccine set for use in this method |
US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
JPH06500128A (en) | 1991-05-08 | 1994-01-06 | シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン | Immune stimulating and immunoenhancing reconstituted influenza virosomes and vaccines containing the same |
DE69233254T2 (en) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5672805A (en) | 1991-07-18 | 1997-09-30 | The Regents Of The University Of California | Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein |
US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
AU671093B2 (en) | 1992-01-07 | 1996-08-15 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
US5679348A (en) | 1992-02-03 | 1997-10-21 | Cedars-Sinai Medical Center | Immunotherapy for recurrent HSV infections |
KR950700081A (en) | 1992-02-11 | 1995-01-16 | W 로우 죤 | Dual Carrier Immunogenic Constructs |
KR950700082A (en) | 1992-02-28 | 1995-01-16 | 로버트 씨. 비숍 | How to Treat Autoimmune Diseases by Bystander |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5851787A (en) | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
GB9209118D0 (en) | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
PT652758E (en) | 1992-06-18 | 2000-04-28 | Harvard College | DIFTERIA TOXIN VACCINES |
CZ282235B6 (en) | 1992-06-25 | 1997-06-11 | Smithkline Beecham Biologicals (S.A.) | Inoculation substance, process of its preparation and use |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
WO1994001772A1 (en) | 1992-07-13 | 1994-01-20 | The Children's Medical Center Corporation | SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
ES2127829T3 (en) | 1992-07-31 | 1999-05-01 | Medeva Holdings Bv | EXPRESSION OF RECOMBINANT PROTEINS FUSED IN ATTENUATED BACTERIA. |
ATE258188T1 (en) * | 1992-08-27 | 2004-02-15 | Deakin Res Ltd | RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS |
US5958883A (en) | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
WO1994009364A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein |
US5605811A (en) | 1992-10-26 | 1997-02-25 | Athena Neurosciences, Inc. | Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein |
DK1298436T3 (en) | 1992-10-26 | 2010-10-25 | Elan Pharm Inc | Process for Identifying Inhibitor Compounds for the Release of Beta-Amyloid Peptide (BAP) |
US5972336A (en) | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
EP1360963B1 (en) | 1993-01-22 | 2007-09-12 | Sloan-Kettering Institute For Cancer Research | Ganglioside-KLH conjugate vaccines with QS-21 for delaying recurrence of melanoma |
US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5472693A (en) | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
WO1994021680A1 (en) | 1993-03-17 | 1994-09-29 | The Government Of The United States Of America As | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
CA2158475C (en) | 1993-03-18 | 2009-06-02 | Lawrence Tamarkin | Composition and method for reducing toxicity of biologically-active factors |
PT812593E (en) | 1993-03-23 | 2002-01-30 | Smithkline Beecham Biolog | VACCINES CONTAINING 3-O-DEACILED MONOPHOSPHALOR-LIPID IN ITS COMPOSITION |
IT1270939B (en) | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | PROCEDURE FOR THE PREPARATION OF IMMUNOGEN AND DIAGNOSTIC REAGENTS, AND IMMUNOGEN AND DIAGNOSTIC REAGENTS SO OBTAINABLE. |
DK0705109T4 (en) | 1993-05-25 | 2004-05-10 | Wyeth Corp | Adjuvants for vaccines against respiratory syncytial virus |
AU7043894A (en) | 1993-05-28 | 1994-12-20 | Miriam Hospital, The | Composition and method for (in vivo) imaging of amyloid deposits |
PT700445E (en) | 1993-06-04 | 2002-07-31 | Whitehead Biomedical Inst | STRESS PROTEINS AND THEIR USES |
US5464823A (en) | 1993-07-20 | 1995-11-07 | The Regents Of The University Of California | Mammalian antibiotic peptides |
JPH09500540A (en) | 1993-07-30 | 1997-01-21 | メデヴァ ホールディングス ビー.ヴイ. | Vaccine composition |
WO1995005393A2 (en) | 1993-08-18 | 1995-02-23 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Lipopolysaccharide-binding and neutralizing peptides |
DK96493D0 (en) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE |
AU707083B2 (en) | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
WO1995005853A1 (en) | 1993-08-26 | 1995-03-02 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
WO1995006407A1 (en) | 1993-08-30 | 1995-03-09 | The Regents Of The University Of California | Novel component of amyloid in alzheimer's disease and methods for use of same |
CN1105728C (en) | 1993-09-07 | 2003-04-16 | 史密丝克莱恩比彻姆公司 | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5652334A (en) | 1993-09-08 | 1997-07-29 | City Of Hope | Method for design of substances that enhance memory and improve the quality of life |
US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
US5470951A (en) | 1993-09-29 | 1995-11-28 | City Of Hope | Peptides for antagonizing the effects of amyloid βprotein |
US5858981A (en) | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
ATE213507T1 (en) | 1993-10-20 | 2002-03-15 | Univ Duke | METHOD FOR BINDING MATERIAL TO BETA-AMYLOID PEPTIDE |
CA2172507C (en) | 1993-10-22 | 2008-12-02 | Jeffrey L. Cleland | Methods and compositions for microencapsulation of antigens for use as vaccines |
US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
CA2182311A1 (en) * | 1994-01-27 | 1995-08-03 | Karen Hsiao | Transgenic non-human mammals with progressive neurologic disease |
CA2182731A1 (en) | 1994-02-03 | 1995-08-10 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
AUPM411994A0 (en) | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
US5795954A (en) | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
US6270757B1 (en) * | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
ATE202940T1 (en) | 1994-05-25 | 2001-07-15 | John Mcmichael | MEANS AND METHODS FOR TREATING PLAQUE DISEASES |
US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US6417178B1 (en) * | 1994-07-19 | 2002-07-09 | University Of Pittsburgh | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
NZ290089A (en) | 1994-07-27 | 1999-05-28 | Queensland Inst Med Res | Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines |
DK0784684T3 (en) | 1994-09-16 | 2007-12-17 | Cancer Res Inst Of Contra Cost | Recombinant peptides derived from the Mc3 anti BA46 antibody, methods for its use, and methods for humanizing antibody peptides |
US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
EP0820299B1 (en) | 1995-02-06 | 2002-04-24 | Genetics Institute, Inc. | Formulations for il-12 |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
ES2175083T3 (en) | 1995-03-14 | 2002-11-16 | Praecis Pharm Inc | AMULOID AGGREGATION MODULATORS. |
US5928913A (en) | 1995-03-23 | 1999-07-27 | Efstathiou; Stacey | Vectors for gene delivery |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
ATE274064T1 (en) | 1995-05-23 | 2004-09-15 | Morphosys Ag | MULTIMER PROTEINS |
WO1996039176A1 (en) | 1995-06-05 | 1996-12-12 | Brigham & Women's Hospital | USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION |
WO1996040895A1 (en) | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics using transgenic animal models |
US5948763A (en) | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
US5910427A (en) | 1995-06-22 | 1999-06-08 | La Jolla Institute For Allergy And Immunology | Antigen non-specific glycosylation inhibiting factor derivatives |
ES2174027T3 (en) | 1995-06-30 | 2002-11-01 | American Cyanamid Co | STABLE COMPOSITIONS CONTAINING MACROLIDES AND MACROLIDES COMBINED WITH VACCINES. |
ATE305039T1 (en) | 1995-07-07 | 2005-10-15 | Darwin Molecular Corp | GENE LOCALIZED ON CHROMOSOME 1 WHICH GENES PRODUCT IS ASSOCIATED WITH ALZHEIMER'S DISEASE. |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AUPN443995A0 (en) | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
AU6898996A (en) | 1995-08-21 | 1997-03-12 | Cytrx Corporation | Compositions and methods for growth promotion |
ATE263374T1 (en) | 1995-09-14 | 2004-04-15 | Univ California | ANTIBODIES SPECIFIC TO NATIVE PRP-SC |
US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
EP0854919A1 (en) | 1995-10-10 | 1998-07-29 | Novartis AG | Melanoma-associated protein |
US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5750361A (en) | 1995-11-02 | 1998-05-12 | The Regents Of The University Of California | Formation and use of prion protein (PRP) complexes |
PT859959E (en) | 1995-11-10 | 2003-12-31 | Elan Corp Plc | PEPTIDES THAT INCREASE TRANSPORTATION THROUGH TISSUES AND METHODS FOR THEIR IDENTIFICATION AND USES |
WO1997018855A1 (en) | 1995-11-21 | 1997-05-29 | Eduard Naumovich Lerner | Device for enhanced delivery of biologically active substances and compounds in an organism |
WO1997021728A1 (en) | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
WO1997032017A1 (en) | 1996-02-26 | 1997-09-04 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides |
US6150091A (en) | 1996-03-06 | 2000-11-21 | Baylor College Of Medicine | Direct molecular diagnosis of Friedreich ataxia |
HUP9902438A3 (en) | 1996-03-29 | 2000-03-28 | Bayer Ag | Parapoxvirus vectors |
JP2000509022A (en) | 1996-04-03 | 2000-07-18 | アナージェン,インコーポレイテッド | Cyclic peptide vaccine for the treatment and prevention of diabetes |
AU735733B2 (en) | 1996-04-19 | 2001-07-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Antigenically reactive regions of the hepatitis A virus polyprotein |
US6284533B1 (en) | 1996-05-01 | 2001-09-04 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
WO1998002462A1 (en) | 1996-07-16 | 1998-01-22 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Immunoglobulin superfamily domains and fragments with increased solubility |
CA2262006A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
GB9617616D0 (en) | 1996-08-22 | 1996-10-02 | Osteometer Biotech As | Assaying protein fragments in body fluids |
CA2183901A1 (en) | 1996-08-22 | 1998-02-23 | Johanna E. Bergmann | Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans |
ES2245003T3 (en) | 1996-08-27 | 2005-12-16 | Praecis Pharmaceuticals Incorporated | MODULATORS OF THE AGGREGATION OF BETA-AMYLOOID PEPTIDES THAT INCLUDE D-AMINO ACIDS. |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
US6797495B2 (en) | 1996-11-05 | 2004-09-28 | The Regents Of The University Of California | Somatic cells with ablated PrP gene and methods of use |
US6022859A (en) | 1996-11-15 | 2000-02-08 | Wisconsin Alumni Research Foundation | Inhibitors of β-amyloid toxicity |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
US6962984B2 (en) | 1996-12-05 | 2005-11-08 | Nihon University | IgA nephropathy-related DNA |
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
EP0966447B1 (en) | 1997-03-03 | 2003-03-05 | Boehringer Ingelheim Pharmaceuticals Inc. | Small molecules useful in the treatment of inflammatory disease |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5798102A (en) | 1997-03-04 | 1998-08-25 | Milkhaus Laboratory, Inc. | Treatment of cardiomyopathy |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
SI0994728T1 (en) | 1997-04-09 | 2009-02-28 | Intellect Neurosciences Inc | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
ATE370740T1 (en) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS |
CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
AU8269898A (en) | 1997-06-27 | 1999-01-19 | Regents Of The University Of California, The | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
IT1293511B1 (en) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | MONOCLONAL CATALYTIC ANTIBODIES WITH PROTEASIC ACTIVITY FOR THE SELECTIVE LYSIS OF THE PROTEIN COMPONENT OF PLATES AND RELATED AGGREGATES |
WO1999006545A2 (en) | 1997-08-01 | 1999-02-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
CA2297070A1 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
CA2654522C (en) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
US6175057B1 (en) | 1997-10-08 | 2001-01-16 | The Regents Of The University Of California | Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy |
US6118044A (en) * | 1997-11-14 | 2000-09-12 | Sankyo Company, Limited | Transgenic animal allergy models and methods for their use |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6710226B1 (en) * | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
DE69831971T2 (en) | 1997-12-03 | 2006-07-06 | Neuralab Ltd., Flatts | SUPPRESSION OF CHANGES ASSOCIATED WITH BETA AMYLOID AT ALZHEIMER |
BR9815345A (en) | 1997-12-03 | 2000-11-21 | Fujisawa Pharmaceutical Co | Soft composition of pelleted drug, inhaler using it and method for its manufacture |
FR2777015B3 (en) | 1998-02-23 | 2000-09-15 | Financ De Biotechnologie | METHOD AND MEANS FOR OBTAINING CELLULAR AND ANIMAL MODELS OF NEURODEGENERATIVE DISEASES |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20050059591A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
EP1073464B1 (en) | 1998-04-28 | 2004-10-06 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
NO314086B1 (en) | 1998-05-08 | 2003-01-27 | Gemvax As | Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for |
JP2003532618A (en) | 1998-05-19 | 2003-11-05 | イエダ リサーチ アンド デベロプメント カンパニイ リミテッド | Cells, nervous system-specific antigens and their uses |
JP2002515235A (en) | 1998-05-21 | 2002-05-28 | ザ ユニヴァーシティ オブ テネシー リサーチ コーポレイション | Amyloid removal method using anti-amyloid antibody |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6432710B1 (en) | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
JP2002526419A (en) | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
EP1148891B1 (en) | 1999-01-19 | 2004-03-17 | PHARMACIA & UPJOHN COMPANY | Method of packaging an oxidation sensitive medicinal substance |
JP2002535289A (en) | 1999-01-22 | 2002-10-22 | ドウアリング,マシユー・ジヨン | Vaccine-mediated treatment of neurological disorders |
US7629311B2 (en) | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2000068263A2 (en) | 1999-05-05 | 2000-11-16 | Neurochem, Inc. | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
AR024558A1 (en) | 1999-06-01 | 2002-10-16 | Neuralab Ltd | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME |
DE60040024D1 (en) | 1999-06-16 | 2008-10-02 | Boston Biomedical Res Inst | IMMUNOLOGICAL CONTROL OF THE BETA-AMYLOID CONTENT IN VIVO |
EP1368486A4 (en) | 1999-07-15 | 2009-04-01 | Genetics Inst Llc | Formulations for il-11 |
JP4796725B2 (en) | 1999-08-04 | 2011-10-19 | ユニバーシティ オブ サザン カリフォルニア | Amyloid β protein (spherical assembly and use thereof) |
DE60044057D1 (en) | 1999-09-03 | 2010-05-06 | Univ Ramot | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER DISEASE |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
AU784312B2 (en) | 1999-11-29 | 2006-03-09 | Bellus Health (International) Limited | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
ES2275570T3 (en) | 1999-12-08 | 2007-06-16 | Intellect Neurosciences, Inc. | BETA CHEMERIC AMYLOID PEPTIDES. |
US6399314B1 (en) * | 1999-12-29 | 2002-06-04 | American Cyanamid Company | Methods of detection of amyloidogenic proteins |
AU783144B2 (en) | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
CN1279971C (en) | 2000-02-21 | 2006-10-18 | 法麦克萨有限公司 | Novel method for down-regulation of amyloid |
SK288723B6 (en) * | 2000-02-24 | 2020-01-07 | Univ Washington | Pharmaceutical preparation and use of said pharmaceutical preparation |
AU2001253158A1 (en) | 2000-04-05 | 2001-10-23 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
EP1385541B1 (en) | 2000-04-13 | 2008-06-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
ATE286072T1 (en) | 2000-05-22 | 2005-01-15 | Univ New York | SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGUE TO AMYLOID BETA AND THEIR USE TO INDUCE AN IMMUNE RESPONSE AGAINST AMYLOID BETA AND AMYLOID AGGREGATES |
WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US20030092145A1 (en) | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
ATE441663T1 (en) * | 2000-09-06 | 2009-09-15 | Aventis Pharma Sa | METHODS AND COMPOSITIONS FOR AMYLOIDOSIS-RELATED DISEASES |
IT1319277B1 (en) | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | MELTING PROTEINS USEFUL FOR ALZHEIMER'S MILK IMMUNIZATION TREATMENT. |
IL139308A0 (en) | 2000-10-26 | 2001-11-25 | Marikovsky Moshe | Peptides from amyloid precursor protein which inhibit tumor growth and metastasis |
EP1347731B1 (en) | 2000-11-02 | 2007-04-25 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
PT1346041E (en) | 2000-11-27 | 2007-06-05 | Praecis Pharm Inc | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
PE20020574A1 (en) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6900036B2 (en) | 2000-12-27 | 2005-05-31 | University Of Texas Health Science Center Houston | Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers |
WO2002059621A2 (en) | 2001-01-24 | 2002-08-01 | Bayer Corporation | Regulation of transthyretin to treat obesity |
DE60121729T2 (en) | 2001-04-19 | 2007-11-29 | Dr. Hermann Schätzl | Prion protein dimers for vaccinations |
ATE420114T1 (en) | 2001-04-30 | 2009-01-15 | Lilly Co Eli | HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA-AMYLOID PEPTIDE&X9; |
DE60229051D1 (en) * | 2001-04-30 | 2008-11-06 | Lilly Co Eli | HUMANIZED ANTIBODIES |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
US20030135035A1 (en) | 2001-08-09 | 2003-07-17 | Mark Shannon | Human ZZAP1 protein |
EP1519740A4 (en) | 2001-08-17 | 2005-11-09 | Lilly Co Eli | Rapid improvement of cognition in conditions related to a-beta |
CA2452104A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
US6907297B2 (en) | 2001-09-28 | 2005-06-14 | Ethicon, Inc. | Expandable intracardiac return electrode and method of use |
US7781413B2 (en) | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
CA2466841A1 (en) | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
US20040001828A1 (en) | 2002-02-21 | 2004-01-01 | Joseph Tuscano | Treatment methods using anti-CD22 antibodies |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
BR0312792A (en) | 2002-07-19 | 2005-05-03 | Cytos Biotechnology Ag | Vaccine compositions containing beta1-6 amyloid antigenic series |
EP1911765A3 (en) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
JP2006508072A (en) | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | Amyloid beta-derived diffusible ligands (ADDLs), ADDL substitutes, ADDL-binding molecules, and uses thereof |
US20060019850A1 (en) | 2002-10-31 | 2006-01-26 | Korzenski Michael B | Removal of particle contamination on a patterned silicon/silicon dioxide using dense fluid/chemical formulations |
FR2846667B1 (en) | 2002-11-06 | 2004-12-31 | Pasteur Institut | VARIABLE FRAGMENTS OF SINGLE-CHAIN CAMELIDE ANTIBODIES DIRECTED AGAINST BETA-AMYLOID PEPTIDE 1-42 AND THEIR APPLICATIONS FOR DIAGNOSIS AND TREATMENT OF NEUROAGREGATIVE DISEASES |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
US6787129B1 (en) | 2003-01-13 | 2004-09-07 | Zenitech Llc | Castor polyester as gloss agents in anionic systems |
CA2513722A1 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
US7575747B2 (en) | 2003-02-10 | 2009-08-18 | Applied Molecular Evolution | Aβ binding molecules |
PT1610820E (en) | 2003-04-04 | 2010-12-16 | Novartis Ag | High concentration antibody and protein formulations |
EP1480041A1 (en) | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
US20060182321A1 (en) | 2003-07-07 | 2006-08-17 | Agency For Science, Technology And Research | Method and apparatus for extracting third ventricle information |
WO2005014041A2 (en) | 2003-07-24 | 2005-02-17 | Novartis Ag | Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
EP1670827A2 (en) | 2003-09-05 | 2006-06-21 | Eli Lilly And Company | Anti-ghrelin antibodies |
CA2445743A1 (en) | 2003-10-08 | 2005-04-08 | The University Of British Columbia | Methods for modulating neuronal responses |
MXPA06006821A (en) | 2003-12-17 | 2006-08-23 | Elan Pharm Inc | Abeta IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME. |
EP1701968B1 (en) | 2003-12-17 | 2015-06-03 | Wyeth LLC | Immunogenic peptide carrier conjugates and methods of producing same |
US20050214222A1 (en) | 2004-02-13 | 2005-09-29 | Mckinnon Stuart J | In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes |
AU2005270026A1 (en) | 2004-07-02 | 2006-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies |
SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
EP1797182A2 (en) | 2004-10-05 | 2007-06-20 | Wyeth a Corporation of the State of Delaware | Methods and compositions for improving recombinant protein production |
US20060160161A1 (en) | 2004-10-26 | 2006-07-20 | Elan Pharmaceuticals, Inc. | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
TW200636066A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized antibodies that recognize beta amyloid peptide |
TW200635608A (en) | 2004-12-15 | 2006-10-16 | Neuralab Ltd | Aβ antibodies for use in improving cognition |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006066233A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
GT200600033A (en) | 2005-01-28 | 2006-10-25 | POLYPEPTIDE STABILIZED LIQUID FORMULATIONS | |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
EA015148B1 (en) | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | METHODS OF PURIFYING Aβ BINDING PROTEIN HAVING A Fc REGION |
EP1910364B1 (en) | 2005-07-18 | 2012-03-21 | Merck Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
WO2007059000A2 (en) | 2005-11-10 | 2007-05-24 | Roskamp Research, Llc | Modulation of angiogenesis by a-beta peptide fragments |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
WO2010044803A1 (en) | 2008-10-17 | 2010-04-22 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
EP2120717A1 (en) | 2007-03-12 | 2009-11-25 | National Institute of Radiological Sciences | Pet visualization of amyloid-associated neuroinflammation in the brain |
BRPI0810118A8 (en) | 2007-04-18 | 2015-09-29 | Janssen Alzheimer Immunotherap | METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
DK2323696T3 (en) | 2008-09-18 | 2018-11-26 | Cedars Sinai Medical Center | OPTICAL PROCEDURE FOR DETECTING ALZHEIMER'S DISEASE |
-
2003
- 2003-03-11 MY MYPI20030834A patent/MY139983A/en unknown
- 2003-03-12 BR BRPI0308143-5A patent/BR0308143A/en not_active IP Right Cessation
- 2003-03-12 MX MXPA04008740A patent/MXPA04008740A/en active IP Right Grant
- 2003-03-12 KR KR1020117003856A patent/KR20110027846A/en not_active Application Discontinuation
- 2003-03-12 PE PE2003000251A patent/PE20040207A1/en not_active Application Discontinuation
- 2003-03-12 CN CN038058162A patent/CN1703426B/en not_active Expired - Fee Related
- 2003-03-12 US US10/388,214 patent/US7256273B2/en not_active Expired - Fee Related
- 2003-03-12 GE GEAP8440A patent/GEP20084474B/en unknown
- 2003-03-12 AU AU2003214152A patent/AU2003214152B2/en not_active Ceased
- 2003-03-12 CA CA2478049A patent/CA2478049C/en not_active Expired - Fee Related
- 2003-03-12 NZ NZ535769A patent/NZ535769A/en not_active IP Right Cessation
- 2003-03-12 ES ES03711559T patent/ES2389541T3/en not_active Expired - Lifetime
- 2003-03-12 UY UY27721A patent/UY27721A1/en not_active Application Discontinuation
- 2003-03-12 JP JP2003575912A patent/JP2006503549A/en active Pending
- 2003-03-12 AR ARP030100863A patent/AR038953A1/en not_active Application Discontinuation
- 2003-03-12 KR KR1020047014176A patent/KR101122871B1/en not_active IP Right Cessation
- 2003-03-12 PL PL375159A patent/PL215258B1/en unknown
- 2003-03-12 EA EA200401170A patent/EA010902B1/en not_active IP Right Cessation
- 2003-03-12 EP EP03711559A patent/EP1554311B1/en not_active Expired - Lifetime
- 2003-03-12 IL IL16362603A patent/IL163626A0/en unknown
- 2003-03-12 WO PCT/US2003/007715 patent/WO2003077858A2/en active Search and Examination
- 2003-03-12 SG SG2006077101A patent/SG180018A1/en unknown
- 2003-03-12 ZA ZA200406616A patent/ZA200406616B/en unknown
- 2003-03-12 TW TW092105368A patent/TWI328116B/en not_active IP Right Cessation
- 2003-12-03 UA UA20041008271A patent/UA89469C2/en unknown
-
2004
- 2004-08-19 IL IL163626A patent/IL163626A/en not_active IP Right Cessation
- 2004-09-21 EC EC2004005314A patent/ECSP045314A/en unknown
- 2004-09-23 NO NO20043992A patent/NO20043992L/en unknown
- 2004-10-11 IS IS7499A patent/IS7499A/en unknown
- 2004-10-12 CO CO04101910A patent/CO5611164A2/en active IP Right Grant
- 2004-10-12 HR HR20040950A patent/HRP20040950A2/en not_active Application Discontinuation
-
2006
- 2006-05-03 HK HK06105249.2A patent/HK1085222A1/en not_active IP Right Cessation
-
2007
- 2007-08-13 US US11/893,123 patent/US8128928B2/en not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
"Fundamental Immunology", 1989, RAVEN PRESS |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 |
J MOL. BIOL., vol. 186, 1989, pages 651 |
NATURE, vol. 342, 1989, pages 878 |
Cited By (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US8034339B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US9051363B2 (en) | 1997-12-02 | 2015-06-09 | Janssen Sciences Ireland Uc | Humanized antibodies that recognize beta amyloid peptide |
US8535673B2 (en) | 1997-12-02 | 2013-09-17 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US8034348B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US8642044B2 (en) | 1997-12-02 | 2014-02-04 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
JP2007525160A (en) * | 2003-03-12 | 2007-09-06 | ニユーララブ・リミテツド | Humanized antibody that recognizes β-amyloid peptide |
JP2007536895A (en) * | 2003-05-30 | 2007-12-20 | ニユーララブ・リミテツド | Humanized antibody that recognizes beta amyloid peptide |
US7871615B2 (en) | 2003-05-30 | 2011-01-18 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
EA016357B1 (en) * | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
JP2008511291A (en) * | 2004-07-30 | 2008-04-17 | ライナット ニューロサイエンス コーポレイション | Antibodies directed against amyloid-beta peptide and methods using the antibodies |
EP2298807A3 (en) * | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
KR101068289B1 (en) * | 2004-07-30 | 2011-09-28 | 리나트 뉴로사이언스 코퍼레이션 | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006036291A3 (en) * | 2004-07-30 | 2006-07-20 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
JP2008511328A (en) * | 2004-08-27 | 2008-04-17 | ワイス・リサーチ・アイルランド・リミテッド | Preparation of anti-amyloid beta antibody |
EP2348126A3 (en) * | 2004-08-27 | 2011-10-12 | Wyeth Research Ireland Limited | Production of anti-amyloid beta antibodies |
JP2015133980A (en) * | 2004-08-27 | 2015-07-27 | ファイザー・アイルランド・ファーマシューティカルズ | Method for producing anti-amyloid beta antibody |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
CN101048512B (en) * | 2004-08-27 | 2013-04-17 | 辉瑞爱尔兰药品合伙公司 | Production of anti-amyloid beta antibodies |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
KR100998857B1 (en) | 2004-08-27 | 2010-12-08 | 와이어쓰 리서치 아일랜드 리미티드 | Production of anti-amyloid beta antibodies |
JP2012095671A (en) * | 2004-08-27 | 2012-05-24 | Wyeth Research Ireland Ltd | Formula for anti-amyloid beta antibodies |
EP2357250A3 (en) * | 2004-08-27 | 2014-07-02 | Pfizer Ireland Pharmaceuticals | Production of polypeptides |
WO2006026408A3 (en) * | 2004-08-27 | 2006-05-04 | Wyeth Res Ireland Ltd | Production of anti-amyloid beta antibodies |
JP2008515430A (en) * | 2004-10-05 | 2008-05-15 | エラン ファーマ インターナショナル リミテッド | Methods and compositions for improving recombinant protein production |
JP2008524247A (en) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | Amyloid beta antibody for use in cognitive improvement |
JP2008523815A (en) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | Humanized amyloid beta antibody for use in improving cognition |
WO2006066049A3 (en) * | 2004-12-15 | 2006-10-05 | Neuralab Ltd | Humanized antibodies that recognize beta amyloid peptide |
US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
WO2006066089A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006066171A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
US8318164B2 (en) | 2005-01-28 | 2012-11-27 | Janssen Alzheimer Immunotherapy | Anti A beta antibody formulation |
EP2392353A1 (en) | 2005-01-28 | 2011-12-07 | Janssen Alzheimer Immunotherapy | Anti A beta antibody formulation |
EA016193B9 (en) * | 2005-04-29 | 2012-08-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006118959A3 (en) * | 2005-04-29 | 2007-05-10 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CN102617733A (en) * | 2005-04-29 | 2012-08-01 | 瑞纳神经科学公司 | Antibodies directed against amyloid-beta peptide and methods using same |
WO2006118959A2 (en) * | 2005-04-29 | 2006-11-09 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
AU2006242546B2 (en) * | 2005-04-29 | 2011-04-21 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
EA016193B1 (en) * | 2005-04-29 | 2012-03-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
KR101130874B1 (en) | 2005-04-29 | 2012-03-28 | 리나트 뉴로사이언스 코퍼레이션 | Antibodies directed against amyloid-beta peptide and methods using same |
TWI501975B (en) * | 2005-04-29 | 2015-10-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CN102617733B (en) * | 2005-04-29 | 2016-01-20 | 瑞纳神经科学公司 | Antibodies directed against amyloid-beta peptide and using method thereof |
EP2388274A1 (en) | 2005-06-17 | 2011-11-23 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A Beta antibodies |
US7820799B2 (en) | 2005-06-17 | 2010-10-26 | Janssen Alzheimer Immunotherapy | Methods of purifying Fc region containing proteins |
US8440799B2 (en) | 2005-06-17 | 2013-05-14 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A β antibodies |
US7825223B2 (en) | 2005-06-17 | 2010-11-02 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A β antibodies |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7744890B2 (en) | 2006-10-12 | 2010-06-29 | Wyeth Llc | Methods and compositions with reduced opalescence |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US10131708B2 (en) | 2007-01-05 | 2018-11-20 | University Of Zürich | Methods of treating Alzheimer's disease |
US9828420B2 (en) | 2007-01-05 | 2017-11-28 | University Of Zürich | Method of providing disease-specific binding molecules and targets |
US10202445B2 (en) | 2007-01-05 | 2019-02-12 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
US9670272B2 (en) | 2007-01-05 | 2017-06-06 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
WO2008084402A3 (en) * | 2007-01-11 | 2009-04-09 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
AU2008204335B2 (en) * | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
US8491903B2 (en) | 2007-01-11 | 2013-07-23 | Philipps-Universitaet Marburg | Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody |
US7939075B2 (en) | 2007-01-11 | 2011-05-10 | Philipps-Universitaet Marburg | Human monoclonal anti-amyloid-beta antibodies |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2481408A2 (en) | 2007-03-01 | 2012-08-01 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US9585956B2 (en) | 2007-06-12 | 2017-03-07 | Ac Immune S.A. | Polynucleotides encoding anti-amyloid beta monoclonal antibodies |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
EP2182983A1 (en) * | 2007-07-27 | 2010-05-12 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2182983A4 (en) * | 2007-07-27 | 2011-03-02 | Janssen Alzheimer Immunotherap | Treatment of amyloidogenic diseases |
US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9644025B2 (en) | 2007-10-17 | 2017-05-09 | Wyeth Llc | Immunotherapy regimes dependent on ApoE status |
EP2952524A1 (en) | 2007-10-17 | 2015-12-09 | Janssen Sciences Ireland UC | Immunotherapy regimes dependent on apoe status |
US9090680B2 (en) | 2008-02-08 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to abeta oligomers and uses thereof |
US10336820B2 (en) | 2008-02-20 | 2019-07-02 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US9090679B2 (en) | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2419447A4 (en) * | 2009-04-17 | 2014-02-26 | Immunas Pharma Inc | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2419447A1 (en) * | 2009-04-17 | 2012-02-22 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
US9211330B2 (en) | 2010-03-03 | 2015-12-15 | Ablynx N.V. | A-beta binding polypeptides |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012000094A1 (en) * | 2010-06-30 | 2012-01-05 | Mount Sinai Hospital | REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α |
US8889132B2 (en) | 2010-06-30 | 2014-11-18 | Mount Sinai Hospital | Antibodies against human HIF-1α |
US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
JP2012034697A (en) * | 2011-09-16 | 2012-02-23 | Janssen Alzheimer Immunotherapy | HUMANIZED ANTIBODY RECOGNIZING β-AMYLOID PEPTIDE |
EP3594240A1 (en) | 2013-05-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
EP4324480A2 (en) | 2013-05-20 | 2024-02-21 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016081643A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US10842871B2 (en) | 2014-12-02 | 2020-11-24 | Biogen International Neuroscience Gmbh | Methods for treating Alzheimer's disease |
WO2016094566A2 (en) | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
US11530257B2 (en) | 2017-06-29 | 2022-12-20 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies for treatment of amyloid deposition diseases |
US11655289B2 (en) | 2017-08-22 | 2023-05-23 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2020072357A1 (en) | 2018-10-04 | 2020-04-09 | University Of Rochester | Improvement of glymphatic delivery by manipulating plasma osmolarity |
WO2020132230A2 (en) | 2018-12-20 | 2020-06-25 | Genentech, Inc. | Modified antibody fcs and methods of use |
RU2783528C1 (en) * | 2019-02-01 | 2022-11-14 | Чанчунь Джинсайенс Фармасьютикал Ко., Лтд. | HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE |
WO2020156222A1 (en) * | 2019-02-01 | 2020-08-06 | 长春金赛药业有限责任公司 | HUMANIZED ANTI-Aβ MONOCLONAL ANTIBODY AND APPLICATION THEREOF |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1554311B1 (en) | Humanized antibodies that recognize beta amyloid peptide | |
US7871615B2 (en) | Humanized antibodies that recognize beta amyloid peptide | |
EP1613347B1 (en) | Humanized antibodies that recognize beta amyloid peptide | |
EP1838854B1 (en) | Antibodies that recognize Beta Amyloid Peptide | |
JP4166569B2 (en) | Humanized antibody that recognizes β-amyloid peptide | |
US20060257396A1 (en) | Abeta antibodies for use in improving cognition | |
EP1838348A1 (en) | Humanized amyloid beta antibodies for use in improving cognition | |
JP2012050437A (en) | Humanized antibody recognizing beta amyloid peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/06616 Country of ref document: ZA Ref document number: 163626 Country of ref document: IL Ref document number: 200406616 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2450/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003214152 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2478049 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003575912 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/008740 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 375159 Country of ref document: PL Ref document number: 1020047014176 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038058162 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 535769 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200401015 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200401170 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-501406 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8440 Country of ref document: GE Ref document number: 2003711559 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20040950A Country of ref document: HR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047014176 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003711559 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: PI0308143 Country of ref document: BR |